

## GUIDELINES

## European Society of Anaesthesiology and European Board of Anaesthesiology guidelines for procedural sedation and analgesia in adults

Jochen Hinkelbein, Massimo Lamperti, Jonas Akeson, Joao Santos, Joao Costa, Edoardo De Robertis, Dan Longrois, Vesna Novak-Jankovic, Flavia Petrini, Michel M.R.F. Struys, Francis Veyckemans, Thomas Fuchs-Buder\* and Robert Fitzgerald†

Procedural sedation and analgesia (PSA) has become a widespread practice given the increasing demand to relieve anxiety, discomfort and pain during invasive diagnostic and therapeutic procedures. The role of, and credentialing required by, anaesthesiologists and practitioners performing PSA has been debated for years in different guidelines. For this reason, the European Society of Anaesthesiology (ESA) and the European Board of Anaesthesiology have created a taskforce of experts that has been assigned to create an evidence-based guideline and, whenever the evidence was weak, a consensus amongst experts on: the evaluation of adult patients undergoing PSA, the role and competences required for the clinicians to safely perform PSA, the commonly used drugs for PSA, the adverse events that PSA can lead to, the minimum monitoring requirements and post-procedure discharge criteria. A search of the literature from 2003 to 2016 was performed by a professional librarian and the retrieved articles were analysed to allow a critical appraisal according to the Grading of Recommendations Assessment, Development and Evaluation method. The Taskforce selected 2248 articles.

Where there was insufficiently clear and concordant evidence on a topic, the Rand Appropriateness Method with three rounds of Delphi voting was used to obtain the highest level of consensus among the taskforce experts.

These guidelines contain recommendations on PSA in the adult population. It does not address sedation performed in the ICU or in children and it does not aim to provide a legal statement on how PSA should be performed and by whom. The National Societies of Anaesthesiology and Ministries of Health should use this evidence-based document to help decision-making on how PSA should be performed in their countries. The final draft of the document was available to ESA members via the website for 4 weeks with the facility for them to upload their comments. Comments and suggestions of individual members and national Societies were considered and the guidelines were amended accordingly. The ESA guidelines Committee and ESA board finally approved and ratified it before publication.

Published online 5 September 2017

This article is accompanied by the following Invited Commentaries:

- De Robertis E, Longrois D, Fuchs-Buder T. Safety and quality of procedural sedation and analgesia practice for adult patients throughout Europe. A step forward. *Eur J Anaesthesiol* 2018; 35:1–3.
- Prakash A, Webb ST. Procedural sedation and analgesia for adults in Europe. Safety first. *Eur J Anaesthesiol* 2018; 35:4–5

From the Department of Anaesthesiology and Intensive Care Medicine, University Hospital of Cologne, Cologne, Germany (JH), Anaesthesiology Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (ML), Department of Clinical Sciences Malmö, Anaesthesiology and Intensive Care Medicine, Lund University Faculty of Medicine, Malmö, Sweden (JA), Centre for Evidence-Based Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal (JS,JC), Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples 'Federico II', Naples, Italy (EDR), Department of Anaesthesiology and Intensive Care, Hôpitaux Universitaires Paris Nord Val de Seine, Paris, France (DL), Clinical Department of Anaesthesiology and Intensive Care, University Medical Centre, Ljubljana, Slovenia (VNJ), Perioperative Medicine, Pain Therapy, RRS and Intensive Care Department, Anaesthesiology and Intensive Care University of Chieti-Pescara, Chieti, Italy (FP), Department of Anaesthesiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands (MMRFS), Anesthésie, Hôpital Jeanne de Flandre, Lille (FV), Fuchs-Buder T. Department of Anaesthesiology and Critical Care, CHRU Nancy, University of Lorraine, Nancy, France (TFB); and Karl Landsteiner Institute for Anaesthesiology and Intensive Care Medicine, Vienna, Austria (RF)

Correspondence to Massimo Lamperti, Anaesthesiology Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates  
Tel: +971 2 5019000x41090; fax: +971 2 4108374; e-mail: docmassimomd@gmail.com

\*Chairman of the ESA/EBA taskforce for procedural sedation and analgesia guidelines in adults.

†Co-chairman of the ESA/EBA taskforce for procedural sedation and analgesia guidelines in adults.

## CONTENTS

<b>Introduction</b> . . . . .	<b>8</b>
<b>Definitions and conceptual framework</b> . . . . .	<b>8</b>
Procedural sedation and analgesia (PSA) . . . . .	8
Stages/levels of sedation . . . . .	9
<b>Methods</b> . . . . .	<b>9</b>
Literature retrieval . . . . .	9
Other methodological considerations . . . . .	9
<b>Questions</b> . . . . .	<b>10</b>
1. What type of comorbidities and patients require evaluation and management of PSA by an anaesthesiologist? . . . . .	10
a. Severe cardiovascular diseases . . . . .	10
b. Documented/risk of Obstructive Sleep Apnoea (OSA) . . . . .	10
c. Morbid obesity . . . . .	11
d. Chronic renal failure . . . . .	11
e. Chronic hepatic disease . . . . .	11
f. Elderly patients . . . . .	11
g. American Society of Anesthesiologists' (ASA) physical status 3 or 4 patients . . . . .	12
2. What are the requirements to provide safe PSA? . . . . .	12
a. Adequate evaluation of the upper airway . . . . .	12
b. Adequate location/monitoring/anaesthesia environment . . . . .	12
c. Management of PSA should be the only task of the professional . . . . .	12
d. All personnel in charge of the PSA should be certified for CPR . . . . .	13
e. Acquisition/maintenance of minimum technical skills of nonanaesthesia personnel . . . . .	13
f. Patient information on the PSA and the personnel providing PSA . . . . .	13
g. Immediate access to equipment for resuscitation . . . . .	14
h. Location and environment for PSA . . . . .	14
i. Pre-PSA fasting . . . . .	14
j. Detailed knowledge of the pharmacology of drugs used for PSA . . . . .	14
k. Detailed knowledge of the monitoring devices and interpretation of the information provided by the monitors as well as interventions . . . . .	15
i. Continuous clinical observation . . . . .	15
ii. Non-invasive blood pressure (NIPB) . . . . .	15
iii. Electrocardiogram . . . . .	15
iv. Pulse oximetry (SpO <sub>2</sub> ) . . . . .	15
vi. Capnography . . . . .	16
v. Processed electroencephalogram (pEEG) monitors . . . . .	16
l. Knowledge of the major type of complications and their management . . . . .	16
i. Respiratory depression . . . . .	16
ii. Airway obstruction . . . . .	17
iii. Arterial hypotension . . . . .	17
iv. Arterial hypertension . . . . .	17
v. Chest pain . . . . .	17
vi. Cardiac arrest . . . . .	17
vii. Allergic reactions . . . . .	17
viii. Other rare or minor complications . . . . .	17
m. Knowledge of the interventions that may be used if required . . . . .	17
i. Oxygen therapy . . . . .	17
ii. Haemodynamic support (outside CPR) . . . . .	17
3. How should recovery after PSA be managed? . . . . .	18
4. Who should evaluate that non-anaesthesia personnel are adequately trained to perform PSA and what criteria should be used? . . . . .	18
5. What are the gaps in knowledge of PSA? . . . . .	18
<b>Summary and Conclusions</b> . . . . .	<b>18</b>

## Introduction

The current document is organised to facilitate reading by clinicians and anticipate possibly necessary updates as part of the new European Society of Anaesthesiology (ESA) Guidelines doctrine<sup>1</sup> on both article and electronic support. The content facilitates navigation through the article, and it is also the basis of the Executive Summary that will contain only the recommendations. The Full Text of the article contains both the recommendations and the arguments together with the references. Finally, the Table of contents can also be used as a framework of training goals for non-anaesthesia personnel and the acquisition/maintenance of their knowledge and technical skills.

There has been increased interest in procedural sedation and analgesia (PSA) over the last 10 years for many reasons, including higher expectations among patients, availability of short-acting drugs, increased numbers of reported major adverse events associated with PSA and a shortage of anaesthesiologists.

The role of anaesthesiologists in PSA has been stated in several guidelines<sup>2,3</sup> but is still challenged, as some Scientific Societies and Organisations<sup>4,5</sup> have promoted the use of rapid-acting hypnotic drugs, such as propofol for PSA by non-anaesthesiologists who should have acquired the mandatory skills (characteristically held by anaesthesiologists) to avoid and if necessary to manage potentially life-threatening adverse events associated with well conducted PSA or with too deep levels of sedation.

Epidemiological data on the incidence of adverse events during PSA are provided mainly by the publications from the American Society of Anesthesiologists' (ASA) Closed Claims study.<sup>6</sup> However, the analysis of the incidence of adverse events related to PSA [designated as monitored anaesthesia care or monitored anaesthesia care (MAC) in the ASA Closed Claims study] is confounded by the fact that the structure of the ASA Closed Claims process cannot provide either the total number of adverse events or the total number of procedures performed. Furthermore, the ASA Closed Claims study only analysed severe adverse events. Despite these limitations, the weight/percentage of severe adverse events associated with MAC in the Closed Claims database has increased over the last decades from approximately 2% of all anaesthetic claims during 1980 to 1989, to 5% during 1990 to 1999 and 10% during 2000 to 2009. Patient death is the most common severe adverse event in the MAC claims, and significantly more common than mortality associated with general or regional anaesthesia.<sup>7</sup> Most fatal incidents result from inadequate oxygenation and/or ventilation in non-operating room areas with suboptimal monitoring facilities and inability to prevent and appropriately manage over-sedation.

The ESA together with the *European Board of Anaesthesiology* (EBA) has created a taskforce with European experts

in PSA. The Taskforce members have defined the objectives of the Guidelines, criteria for the literature search and evidence analysis as well as methods used to provide recommendations. The main objectives of these guidelines are to provide evidence-based recommendations on: the evaluation of adult patients undergoing PSA, the role and competences required for clinicians to safely perform PSA, the minimum monitoring requirements, prevention and management of adverse events from PSA, the commonly used drugs for PSA and post-procedure discharge criteria.

These Guidelines are conceived as an evidence/consensus-based document on which the different European National Societies of Anaesthesiology and the ministries of Health of their respective countries may build their decisions on how professionals can deliver procedural sedation and how PSA can be provided in the safest way according the Helsinki Declaration on Patient Safety in Anaesthesiology.<sup>8</sup> The guidelines may help frame the medicolegal context when considering whether an anaesthesiologist or non-anaesthesiologist performs PSA, and when PSA is to be performed outside an operating room or in an office-based setting. It is however beyond the scope of these Guidelines to provide a focus on light sedation for anxiolytic purposes even if the administration of any sedative drug could cause an unpredicted response, leading to deeper levels of sedation.

## Definitions and conceptual frameworks Procedural sedation and analgesia

The term *procedural sedation and analgesia (PSA)*<sup>9</sup> involves the use of hypnotic and/or analgesic medications to enable effective performance of diagnostic or therapeutic procedures effectively, whilst the patient is closely monitored for potential adverse effects. PSA was previously (and inappropriately) termed *conscious sedation*; indeed, the association of the two terms is contradictory because effective sedation reduces consciousness. Well tolerated PSA results in preservation of airway patency and spontaneous ventilation despite depressed levels of consciousness.

PSA, even when adequately performed, may increase the risk of morbidity and mortality in addition to the diagnostic/therapeutic procedure itself. By recognising the intrinsic risks of PSA, the *Joint Commission on Accreditation of Healthcare Organizations* in the USA mandates that PSA throughout any institution in the United States should be monitored and evaluated by the Department of Anaesthesia. Anaesthesia professionals are not required to be directly responsible for sedation services or their quality assurance, but rather to have an advisory and supportive role.<sup>10</sup> The privileging on who can provide PSA in the United States is regulated by the ASA, which has created a training course that allows the providers to deliver only mild-to-moderate sedation to ASA physical status I and II patients. For high-risk patients (ASA physical status III

and IV), PSA should always be delivered by an anaesthesiologist. The present Guidelines adopt a more detailed definition of the stages of sedation to facilitate correct identification of the patients that must be managed by anaesthesiology professionals.

### Stages/levels of sedation

There are several validated ways to define and assess levels of sedation. For example, below is a modified version of the five-level *Ramsay* scale,<sup>11</sup> where level 5 is similar to, or synonymous with, general anaesthesia:

- (1) Level 1: Fully awake.
- (2) Level 2: Drowsy.
- (3) Level 3: Apparently asleep but rousable by normal speech.
- (4) Level 4: Apparently asleep but responding to standardised physical stimuli (e.g. glabellar tap).
- (5) Level 5: Asleep, but not responding to strong physical stimuli (comatose).

The ASA has defined four levels of sedation,<sup>12</sup> where level 4 corresponds to general anaesthesia (Table 1 – Supplemental Digital File, <http://links.lww.com/EJA/A126>).

Although differences between the first two levels of sedation are not always clear, whenever a patient reaches a deeper level of sedation (levels 3 or 4), there is also higher risk of life-threatening adverse events that mandate immediate and appropriate management. Importantly, management of transition from levels 3 to 4 may require specific knowledge and technical skills (advanced airway/cardiovascular resuscitation) that are in general only fully mastered by an anaesthesiologist.

## Methods

### Literature retrieval

A taskforce was created to develop European guidelines on PSA based on the evidence retrieved from the literature and the clinical expertise of each expert in this domain. Members of the taskforce contributed to define the selection of patients based on risk stratification, competences required to provide well tolerated PSA, drugs used for PSA and management of their adverse effects, monitoring, recovery, and criteria for patient discharge. The taskforce formulated a defined number of population, intervention, complication, outcome (PICO) questions and keywords to guide the literature search from the initial proposals from the ESA subcommittees with subsequent validation by the chairmen of the taskforce and literature reviewers. The taskforce also established inclusion/exclusion criteria for the studies. This process was completed by November 2013. The literature search was in January 2014 and updated in June 2016. A broad filter for PSA was applied in conjunction with a study type filter and a specific subgroup filter based on the questions and keywords. The MEDLINE, EMBASE and Cochrane Library databases were searched from 2003

to June 2016 for the normalised and free-text terms ‘(conscious sedation)’, ‘(deep sedation)’, ‘procedure\*’ ‘intervention\*’ or ‘exam\*’ (Appendix 1 – Supplemental Digital File, <http://links.lww.com/EJA/A126>). A total of 12 263 records were identified (Fig. 2 – flowchart – Supplemental Digital File, <http://links.lww.com/EJA/A126>). Original articles went through a two-round selection process. First, screening of titles and abstracts was carried out by one reviewer (to remove duplicates and select articles according to inclusion criteria) and, when in doubt, checked by a second reviewer. Systematic reviews, randomised controlled trials, cohort studies, case control studies and cross-sectional surveys were included. Existing guidelines were identified and considered separately. Narrative reviews, editorials, case series or case reports were excluded. Only English language articles were included. A total of 2248 articles were selected.

A second round of selection was carried out by each subcommittee to identify articles concerning adults (older than 18 years of age) receiving PSA for any painful or non-painful diagnostic or therapeutic procedure, but excluding dental surgery and other minor interventions carried out under local anaesthesia. Articles covering long-term sedation in intensive care (other than those for specific procedures that could be considered as PSA) were also excluded. As we wished to include all relevant articles, the ESA subcommittees included any article considered potentially relevant. After this two-round selection, 482 full-text articles were made available for the taskforce members. The articles were individually analysed for risk of bias, applicability, external validity and clinical relevance. Studies where the intervention was obsolete were excluded.

### Other methodological considerations

Once the final number of articles was set, evidence was critically appraised using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology.<sup>13–25</sup> As GRADE was used to assess the quality of evidence, the following features were assessed for each outcome:

- (1) GRADE was based on limitations of study design (selection, performance, detection, attrition and reporting of bias), effect consistency and size, directness, precision, publication bias, dose–response effect and presence of antagonistic bias.
- (2) The transformation of evidence into a recommendation was a function of the panel evaluation of the five factors summarised (Section C, Table 2 – Supplemental Digital File, <http://links.lww.com/EJA/A126>).
- (3) Since the GRADE system could not be used to standardise the decision-making process of the expert panel, the ESA/EBA taskforce selected the Rand Appropriateness Method, published in detail elsewhere,<sup>26,27</sup> for that purpose.

To increase the level of the consensus, especially whenever strong evidence was lacking, a three-round Delphi method was used. The expert panel met in Berlin in June 2015 for a first round of anonymous voting after face-to-face debating. The second and third voting rounds were both internet-based and additional internet-based voting rounds were necessary to establish a consensus between the experts of this ESA/EBA Taskforce whenever there was a lack of evidence in the literature. The experts formulated draft recommendations before each process of voting to serve as a foundation for subsequent discussion and evaluation. The expert panel was updated by short presentations of the literature search results and subsequent interpretation for drafting of the proposed recommendations. The voting process included expert judgments on GRADE factors, such as outcome, importance and evidence-to-recommendation transformers (Tables 3 and 4 – Supplemental Digital File, <http://links.lww.com/EJA/A126>). An algorithm (Fig. 1 – Supplemental Digital File, <http://links.lww.com/EJA/A126>) depicted the final rendering of disagreement/agreement graded by the degrees of agreement. This process provided a structured and validated method for expert panel activities. In addition, it standardised statistical methodology for determining the degree of agreement to serve as a foundation for deciding about the grade of recommendation (GoR) (strong versus weak).

## Questions

### 1. What types of co-morbidities and patients require evaluation and management of procedural sedation and analgesia by an anaesthesiologist?

The taskforce provided recommendations that the following groups of patients must be evaluated and managed for PSA by anaesthesiology professionals.

#### 1a. Patients with severe cardiovascular diseases (very good consensus: level of evidence A: grade of recommendation strong)

Patients with cardiovascular diseases should be carefully evaluated and optimised according to a ‘first, do no harm’ (*primum non nocere*) strategy. This involves full evaluation of physical status and cardiac reserve<sup>28</sup> before PSA. In emergency procedures (e.g. gastroscopy for bleeding), this evaluation might have to be limited. In all other cases, a more complex and systematic approach should be considered, including patient history and co-morbidities, physical examination, including blood pressure (BP) measurement and pulmonary auscultation, biochemical testing, and ECG at rest. Urgency, invasiveness and persistence of those procedures, particularly under sub-optimal conditions of PSA, can elicit stress responses with myocardial ischaemia, impairment and failure in cardiac patients.<sup>29,30</sup> Predictive models for preoperative assessment of cardiac risk factors<sup>31,32</sup> may provide objective clinical tools for assessing and predicting individual risks

of cardiac events in patients undergoing non-cardiac procedures under PSA. Cardiac patients may also require PSA for minor or major cardiac procedures such as left heart catheterisation or coronary stenting,<sup>33,34</sup> electrical cardioversion<sup>35</sup> and implantation of internal defibrillators,<sup>36</sup> pacemakers or trans-femoral aortic valves.<sup>37</sup> Current practice for these procedures is to provide PSA with benzodiazepine (mainly midazolam) and/or propofol, and low-dose opioid.<sup>34,37</sup> Dexmedetomidine has been proposed as an adjuvant, but it should be used cautiously as its use has been reported mainly in paediatric patients and it is currently off-label in Europe.<sup>38,39</sup> The essential role of an anaesthesiologist has been previously advocated in patients with moderate to severe hypotension (SBP < 90 mmHg) or major cardiac dysfunction.<sup>40,41</sup>

#### 1b. Patients with documented or suspected risk of obstructive sleep apnoea syndrome (very good consensus: level of evidence B: grade of recommendation strong)

Patients with obstructive sleep apnoea syndrome (OSAS) are more vulnerable to drug-induced cardiopulmonary depression during deep sedation.<sup>42</sup> There are different validated instruments to identify patients at risk of OSAS, like the Berlin<sup>43</sup> or STOP-BANG<sup>44</sup> questionnaires. Those are usually performed during the pre-evaluation of the patient in the pre-anaesthesia clinic. Pre-intervention recognition of OSAS is an essential first step in preventing and managing potential complications. A thorough patient history (e.g. snoring, witnessed apnoeas during sleep) and physical examination are important in raising a suspicion of OSAS, but the absence of typical clinical features does not exclude OSAS. Although the use of ‘conscious sedation’ (in the Guidelines definitions, levels 1 and 2) in OSAS patients did not seem to be related with major and minor cardiopulmonary adverse events<sup>45–48</sup> when the procedure was performed by a non-anaesthesiologist, these data are of limited evidence given their retrospective evaluation and the possible lack of statistical power. The presence of OSAS does not *per se* predict cardiopulmonary complications.<sup>48</sup> However, PSA in OSAS patients may require deeper levels of sedation or even general anaesthesia. Hypoxaemia, arterial hypotension or premature termination of the procedure may occur also with anaesthesiologist providing MAC for patients with OSAS.<sup>49</sup> Fast and adequate management of such complications requires professional skills.

Management of OSAS patients undergoing PSA requires thorough and appropriate understanding of different pharmacological options available, where minimal doses of hypnotics should be used and opioids avoided. Dexmedetomidine has been used with a good safety profile and could be considered as an alternative choice for PSA if OSAS is documented.<sup>50</sup> In patients with severe OSAS, the use of nasal continuous positive airway pressure (CPAP) might reduce risks of post-procedural respiratory

complications but correct management of CPAP usually requires expert skills.<sup>51</sup>

**1c. Patients with morbid obesity (BMI greater than 40 kg m<sup>-2</sup>) (very good consensus: level of evidence A: grade of recommendation strong)**

Morbidly obese patients are at higher risk of respiratory complications during PSA for several reasons, including impaired function of respiratory muscles, reduced functional residual capacity, limitation of expiratory flow,<sup>52–54</sup> increased oxygen consumption, increased production of carbon dioxide, increased work of breathing at rest,<sup>52</sup> increased upper airway resistance with propensity for OSAS,<sup>52–55</sup> and the potential for obesity–hypoventilation syndrome, followed by pulmonary hypertension and right heart failure.<sup>56,57</sup> Although BMI is a robust and simple clinical tool for assessment of obesity, it has limitations when analysed alone (e.g. heavily muscled individuals are classified as being overweight). It is now documented that other factors, such as young age and pattern of adipose tissue distribution, may be better predictors of risk of long-term complications; the waist height/hip ratio is also considered to be more predictive of complications.<sup>58</sup> In particular, central obesity is more strongly related to higher risk of impairment of breathing, which often worsens during PSA. As obese patients with OSAS are more prone to airway obstruction, the use of the Berlin<sup>43</sup> or STOP BANG<sup>49,59</sup> questionnaires is proposed to assess the severity of OSAS before providing PSA in obese patients.

Practical recommendations whenever PSA is to be carried out in obese patients are to avoid the supine position and place the patient in a beach chair position, prefer endotracheal intubation as the default choice of airway management, avoid long-acting sedatives, avoid drugs with respiratory depressant effects on the breathing frequency and/or tidal volume, and avoid drugs that induce or reinforce airway obstruction in non-intubated patients. Propofol for sedation seems to be associated with respiratory complications also when used by anaesthetists, so remifentanyl and dexmedetomidine (as off-label use in Europe) have been proposed for tailored titration of sedation and analgesia with appropriate monitoring of breathing and depth of anaesthesia despite the fact that both drugs are associated with acute respiratory events and their use should be judiciously evaluated in obese patients where the risk for possible difficult ventilation and intubation can be challenging.<sup>60,61</sup>

**1d. Patients with chronic renal failure (glomerular filtration rate below 60 ml min<sup>-1</sup> 1.73 m<sup>-2</sup> for more than 3 months or stage 3A) (very good consensus: level of evidence B: grade of recommendation weak)**

PSA is required to relieve anxiety and minimise discomfort associated with arteriovenous fistula creation and other procedures in patients with chronic renal failure (CRF). Propofol and alfentanil used to achieve a similar degree of sedation and analgesia have been reported to

induce lower SpO<sub>2</sub> values and apnoea/hypoventilation in CRF patients than in control patients.<sup>62</sup> For PSA during procedures of vascular access for haemodialysis, intravenous administration of drugs, such as midazolam and/or fentanyl, are generally preferred for their short onset time, although the maximal effect of midazolam, as estimated by pharmacokinetic and pharmacodynamic models, is about 13 min. No difference has been reported in distribution, elimination or clearance of unbound midazolam between normal patients and CRF patients given intravenous doses of 0.2 mg kg<sup>-1</sup>.<sup>63</sup> The pharmacokinetics of single-dose fentanyl is not affected in CRF.<sup>64–66</sup> Similar to midazolam,<sup>67</sup> fentanyl is primarily metabolised by the liver.<sup>68</sup> Major, mainly cardiovascular and/or pulmonary, adverse effects associated with the administration of either midazolam or fentanyl have been reported to increase when the two drugs are being combined,<sup>69</sup> particularly in high-risk CRF patients, and there is need for careful intra-procedural and post-procedural respiratory monitoring and management of these patients.

**1e. Patients with chronic hepatic disease (model for end-stage liver disease score ≥10) (very good consensus: level of evidence A: grade of recommendation strong)**

Patients with chronic liver disease are often exposed to endoscopic procedures requiring PSA for diagnostic assessment of for example oesophageal varices or portal hypertensive gastropathy.<sup>70</sup> Hepatic dysfunction resulting from liver disease can significantly change metabolism and pharmacokinetic properties of hypnotic drugs. The risk of complications related to sedation is increased in these patients.<sup>71,72</sup> Midazolam is preferred in most centres because it has a shorter onset time when compared with diazepam and lorazepam and it has potent amnesic properties. However, prolonged plasma half-life may increase the risks of adverse effects in hepatic dysfunction.<sup>73–76</sup>

In minimal hepatic encephalopathy, procedural sedation with midazolam caused exacerbation of symptoms for up to 2 h after the end of the procedure.<sup>77,78</sup> Propofol used for sedation has a more favourable pharmacokinetic profile requiring no dose adjustment in renal or hepatic failure. Propofol sedation in chronic hepatic failure (including Child C patients) has been reported to be superior to midazolam sedation in terms of safety, efficacy and recovery.<sup>79–86</sup> Propofol-induced hypoxaemia (decreased SpO<sub>2</sub> values) is not common in hepatic failure but can occur, requiring supplemental oxygen and airway support. Measurement of SpO<sub>2</sub> values before PSA can help detecting a hepatopulmonary syndrome.<sup>79,87</sup>

**1f. Elderly patients (older than 70 years) (very good consensus: level of evidence A: grade of recommendation strong)**

There are many age-related physiological changes in the cardiac, pulmonary, renal, hepatic, endocrine and nervous

systems in elderly patients that need to be evaluated to determine if those patients are at increased risk for complications related to PSA.<sup>88,89</sup> Studies suggest that there are increased risks of arterial hypotension, hypoxaemia, cardiac arrhythmias and aspiration in elderly patients undergoing PSA compared with younger patients.<sup>90–92</sup>

Endoscopic procedures are generally well tolerated in elderly patients, with complication rates similar to those in younger patients.<sup>93–98</sup> An exception is colonoscopy, which is associated with higher perforation rates in patients over 65 years and with higher rates of cardiovascular, pulmonary, and total complications in patients over 80 years compared with younger patients.<sup>99–101</sup> For long procedures, such as endoscopic retrograde cholangiopancreatography, different sedative drugs have been used, and the main concerns seem to be related to reduced doses to avoid over dosage, post-procedural hypoxaemia, and prolonged recovery.<sup>102,103</sup>

It is well known that essential pharmacokinetic and pharmacodynamic changes are associated with the process of ageing. Apparently, the brain becomes more sensitive to hypnotic drugs with age.<sup>104</sup> By evaluating specific effects of propofol by electroencephalography (EEG), Schnider *et al.*<sup>105</sup> have demonstrated increased sensitivity to propofol in elderly patients. An appropriate dose reduction for midazolam and propofol for endoscopies in elderly patients has been extensively studied.<sup>106–108</sup> The onset of action of all anaesthetic drugs used in elderly patients is much slower and the intervals for successive doses (dose-titration) should be adapted accordingly.

**1g. Patients with American Society of Anesthesiologists' physical status III to IV (very good consensus: level of evidence B: grade of recommendation strong)**

High-risk (ASA status 3 or higher) patients undergoing PSA have a higher risk of hypoxaemia due to hypoventilation,<sup>109–111</sup> calling for adequate clinical observation and monitoring, management of airway patency and ventilation patterns. A new tool to assess potential risk related to PSA called the area under the oxygen saturation curve (AUCDesat) has been advocated as a useful predictive composite index for sedation risk assessment, reflecting individual duration and extent of desaturation over time.<sup>112</sup> Its clinical role still needs to be validated in extensive outcome studies.

**2. What are the requirements to provide well tolerated procedural sedation and analgesia?**

**2a. Adequate upper airways evaluation (very good consensus: level of evidence B: grade of recommendation strong)**

The majority of severe complications of PSA are associated with altered upper airway patency and/or respiratory

depression, so evaluation of the upper airway before PSA is essential. Documented systematic assessment of the upper airways should be carried out before any PSA. Methods of systematic airway examination have been designed to identify patients where ventilation by face mask<sup>113–115</sup> and/or endotracheal intubation<sup>116–120</sup> might be difficult with standard techniques, but not all difficult airways can be predicted.<sup>118</sup>

Difficult upper airways management is associated with, but not exclusively limited to, individual deviations in general habitus (significant obesity, pregnancy),<sup>121–124</sup> head and neck anatomy (short thyromental distance, limited cervical range of motion, facial or neck trauma, tumour, oedema, abscess, haematoma, tracheal deviation, large neck circumference, dysmorphic facial features, excessive facial hair), mouth opening (small mouth opening, trismus, macroglossia, protruding incisors, small inter-incisor distance, toothlessness, tonsillar hypertrophy, high arched palate) and jaw anatomy (micrognathia, retrognathia, inability to prognath, that is to advance lower incisors forward beyond upper incisors).<sup>118</sup> For more details, refer to current reference literature in anaesthesia.<sup>118</sup>

**2b. Adequate location/monitoring and anaesthesia environment**

In addition to environmental factors (e.g. locations of PSA facilities and recovery sites, room sizes, spatial logistics and equipment), human and procedural factors (e.g. staff qualifications, immediate access to emergency support) also influence patient safety. A basic rule for well tolerated PSA is that the clinician performing the sedation should only be responsible for PSA: performing both the invasive procedure and the PSA is unsafe. Ministries of Health should state 'safety first' in their hospitals and private clinics.

**2c. All personnel in charge of the procedural sedation and analgesia should be certified for cardiopulmonary resuscitation (very good consensus: level of evidence B: grade of recommendation strong)**

The risk of life-threatening complications during or after PSA is increased if staff are inexperienced and less well trained. Complication rates in low-risk patients are considered to be lower than in high-risk patients.

The main problems encountered in patients during and after PSA include hypoxaemia/decreased SpO<sub>2</sub> values (40.2%), vomiting/aspiration (17.4%), arterial hypotension/haemodynamic instability (15.2%), apnoea (12.4%) and cardiac arrest. Although some complications are non-fatal, they can easily lead to cardiac arrest requiring cardiopulmonary resuscitation (CPR).<sup>125</sup> Therefore, proper training in critical emergency medicine of all staff caring for patients during or after PSA is crucial. Training

should include not only management of cardiac arrest but also prevention, recognition of a deteriorating situation and management of deterioration early in the course. Being able to perform CPR immediately in the case of cardiac arrest also requires specific medical material, including a defibrillator, to be immediately available wherever PSA takes place.

Scenario-based and simulation-based training in endoscopic haemostasis may provide opportunities to improve procedural skills and acquire practical experience in managing this medical emergency, which also requires the ability as a team leader to rapidly process, integrate and appropriately respond to complex information under emergency conditions.<sup>126</sup> However, sole manikin training has been shown not to result in sufficient improvement of skills for managing patients.<sup>127</sup> This underlines the importance of specific attention to the science of human factors.

#### **2d. Minimal skills for training for non-anaesthesia providers dedicated to procedural sedation and analgesia**

*Minimal requirements for provision of PSA include the ability to appropriately perform pre-procedural clinical assessments (including upper airway and co-morbidities assessment); competence at intravenous cannulation; appropriate skills for rapid assessment (by direct clinical observation and monitoring) and management of different levels of sedation; advanced airway management; diagnosis and management of respiratory and haemodynamic depression; detailed knowledge of the pharmacology of drugs used for PSA and for emergency management; certified competence in advanced life support and monitoring of the patient (very good consensus: level of evidence B: GoR strong).*

There is consensus in the literature on the needs for certified training of staff directly involved in PSA.<sup>2,128–133</sup> According to the Academy of Royal Colleges in the United Kingdom, individuals who administer drugs for PSA should be aware of their possible adverse events and be prepared and able to rapidly recognise and manage them.<sup>134</sup> Therefore, this taskforce agrees that each provider delivering PSA must be able to evaluate and manage various levels of sedation (see Section 2). The theoretical training should be assessed by a written formal exam with multiple choice questions with a minimal passing score of 75%.<sup>128</sup>

#### **2e. Acquisition/maintenance of minimum technical skills for non-anaesthesia personnel: procedural sedation and analgesia should be carried out only in locations where an anaesthesiologist is immediately available (very good consensus: level of evidence C: grade of recommendation strong)**

Technical skills mandatory to acquire and maintain competence in delivering well tolerated PSA include at least bag mask ventilation and placement of a supraglottic

airway. Tracheal intubation is not a mandatory requirement but one should be prepared to intubate the patient, for example in case of inhalation of gastric content or any other distress syndrome (anaphylactic shock, bronchospasm). There is evidence that tracheal intubation performed by non-anaesthesiologists is one of the predicting factors for difficult intubation,<sup>135</sup> and there is a need for a certain number of successful intubations before considering the trainee proficient in (advanced) airway management.<sup>136,137</sup> Given the risk of occurrence of major adverse effects during PSA even in healthy patients,<sup>138</sup> a certified competence in advanced life support in all personnel involved in PSA is suggested. Another requirement for well tolerated PSA is the ability to evaluate adequate recovery from PSA. The person responsible for providing PSA should be competent in recognition of full recovery of consciousness<sup>2</sup> using objective tools<sup>139,140</sup> and in case of prolonged or unexpected over sedation, patients should be evaluated according to the Aldrete Score and reach a value of 8 to 10 before allowing discharge from the hospital/office.<sup>141</sup>

Completion of training should be confirmed using a Global Rating Score (GRS) (previously used in other settings<sup>142,143</sup>) that could certify the competence of the trainee dedicated to provide PSA and allow different privileges according to the standard achieved during the final evaluation. This Taskforce suggests that a GRS for evaluating PSA theoretical/technical knowledge should be used before giving privileges for PSA (Appendix 2 – Supplemental Digital File, <http://links.lww.com/EJA/A126>). It is not the aim of these Guidelines to define the legal/regulatory aspects of PSA practice because they may vary from country to country. The teaching bodies must provide a certificate of proficiency that needs to be endorsed by the national Ministry of Health.

Manikin training alone has been shown not to result in sufficient improvement of skills for care of patients,<sup>124</sup> and a competence maintenance certificate is not currently a requirement in training systems. EBA should support maintenance of skills via every national healthcare body in relationship with the Union of European Medical Societies.

#### **2f. Patient information on procedural sedation and analgesia and the personnel dedicated to provide procedural sedation and analgesia**

*The clinician has to discuss with the patient the risk, benefits and techniques to deliver PSA before performing the procedure (very good consensus: level of evidence B: GoR strong).*

Before performing PSA, the clinician has to complete a full clinical evaluation of the patient to discuss the potential harms and the suggested plan for the scheduled procedure. The clinician should also disclose/present potential alternatives in case of failure that could also



include not having any treatment. The legal concept of the reasonable person is used in obtaining informed consent. The reasonable person doctrine focuses on material risks. A material risk is one that the provider knows or ought to know would be significant to a reasonable person in the patients' position of deciding whether to submit to a particular medication or treatment procedure. However, all conceivable risks do not require disclosure. A printed informed consent form should be used and the informed consent needs to be witnessed. Consent form waivers can be considered acceptable wherever the patient is unable to provide explicit consent due to severe pain or altered mental status.<sup>144–146</sup>

## 2g. Immediate access to equipment for resuscitation

*A difficult airway cart should be readily available wherever PSA is performed (good consensus: level of evidence B: GoR strong).*

As airway problems during PSA are quite common and may rapidly lead to severe hypoxaemia, an approved algorithm for difficult airway management should be readily available. If no difficult airway cart is available, specific pre-packed material (e.g. in bags) may be adequate for immediate supply in case of emergency.<sup>147,148</sup>

## 2h. Location and environment for procedural sedation and analgesia

There should be a dedicated room for PSA inside any facility. Those rooms should have easy access, an easy evacuation system in case of emergency and an elevator large enough to evacuate the patient on a stretcher. A code blue button installed in the PSA room can facilitate an alarm in case of emergency (good consensus – level of evidence C – GoR strong).

A code blue button installed in the PSA room can facilitate alarming in case of emergency as an immediate and appropriate response is vital. However, there are different ways to facilitate alarming of emergency teams for help. Having a code blue button, or at least specific and well known alarm procedures, may save patients' lives in emergency situations.<sup>147</sup>

## 2i. Pre-sedation fasting

*Fasting prior to PSA is not evidence-based. A single protocol as used for preoperative fasting prior to surgery should avoid confusion and mistakes (good consensus: level of evidence C: GoR weak).*

The current literature does not provide sufficient evidence to test the hypothesis that pre-procedure fasting results in a decreased incidence of adverse outcomes in patients undergoing PSA.<sup>146–150</sup> Recent guidelines<sup>151</sup> related to preoperative fasting prior to surgery recommend that for adults undergoing elective procedures, the preoperative fasting period is 2 h for clear fluids and 6 h for solid food.

## 2j. Detailed knowledge of the pharmacology of drugs used for procedural sedation and analgesia

It is beyond the scope of these Guidelines to review in detail the pharmacology of sedative and analgesic drugs commonly used to provide adequate comfort to patients subjected to diagnostic or therapeutic PSA and previously described elsewhere.<sup>149–151</sup> Instead, the main goal of this taskforce in this context is to focus on basic pharmacokinetic and pharmacodynamic aspects of sedative and analgesic drugs. To ensure well tolerated drug administration, clinicians should always be aware of the pharmacological properties of each drug and drug combinations used.<sup>69</sup>

Drug selection for PSA should be based on ease of dosing to reach and maintain the desired level of sedation and analgesia, therefore avoiding adverse events caused by excessive dosage or unexpected reactions to the individual drug or drug combination. As such, the theoretically ideal drug for PSA has a rapid onset, short duration of action and time-independent context-sensitive half-time. In addition, it should have a beneficial haemodynamic and respiratory stability profile. As most of the available drugs for PSA do not cover both the hypnotic and analgesic endpoints, drug combinations are mostly required.<sup>152</sup> Therefore, the clinician should understand the principles of drug interactions to balance between clinical effects and side-effects.<sup>153,154</sup>

For most of the drugs used for PSA, the recommended route of administration is intravenously as the pharmacokinetic effect can be better predicted.<sup>149</sup> Some upcoming evidence exists on intranasal drug administration during PSA, for example for dexmedetomidine.<sup>155</sup>

Propofol remains the most common sedative drug,<sup>156–162</sup> mainly for its short onset time (30 to 60 s), predictable duration of action and short context-sensitive half-time. It induces a dose-dependent amnesia and sedation, leading to unconsciousness and general anaesthesia at higher concentrations.<sup>163</sup> As propofol has no analgesic properties, it is mostly combined with opioids during PSA resulting in a strong synergistic relationship of both sedative and analgesic effects. In addition, these drug combinations can induce significant haemodynamic and respiratory instability requiring fine-tuned titration.<sup>164,165</sup> Alternatively, ketamine and dexmedetomidine have been described as adjuvant drugs with propofol. Pain at the site of injection of propofol is a problem, which can be minimised by reducing the concentration to 0.5% or administering lidocaine or opioids intravenously before its administration.

Benzodiazepines are still used for PSA. The most frequently used benzodiazepine is midazolam for its rapid onset (30 to 60 s) and the maximum effect is reached after 13 min. Its duration of action is longer than propofol (20 to 80 min) and with a prolonged half-life; for this reason, it is used mainly for shorter procedures but with caution in

elderly patients or patients with comorbidities.<sup>166,167</sup> As midazolam has no analgesic properties, it is typically combined with opioids during PSA. Before considering it a sole drug for PSA, its low therapeutic index should be considered.

Ketamine differs from other sedatives in several ways. It possesses analgesic properties and can, therefore, be used as the sole agent for painful procedures. It has a rapid onset of action (30 to 60 s) and a moderate duration of action (10 to 20 min). Because of its cardiovascular stimulating effects, ketamine should be used cautiously in patients with ischaemic heart disease.<sup>168,169</sup>

Two  $\alpha_2$ -agonists (clonidine and dexmedetomidine) are used for sedation in clinical practice. Although clonidine has a long duration of action as it is highly lipophilic, dexmedetomidine is more highly bound to plasma proteins.<sup>170</sup> Dexmedetomidine needs to be administered by a slow initial bolus followed by continuous infusion. Its use as 'per se' sedative drug or combined with opioids has recently reached great success in paediatric patients even although the recommended use is for continuous sedation in patients in the ICU.<sup>171</sup> Dexmedetomidine has a beneficial respiratory stability profile, but caution is required as cardiovascular changes related to speed of injection are present.<sup>172</sup>

Different opioids are often used to relieve pain during procedures. Although morphine is the reference drug, synthetic opioids such as fentanyl, alfentanil, sufentanil and remifentanyl are more useful to supplement sedatives for short painful procedures.

Most drugs used during PSA are injected as single or repeated boluses or as a continuous infusion. For propofol and remifentanyl, pharmacokinetic-based, target-controlled infusion has been introduced into clinical routine and has proven to out-perform manual infusion schemes, resulting in fewer episodes of apnoea, better haemodynamic stability, better patient and clinician satisfaction, better monitoring focus and better patient recovery.<sup>173,174</sup>

## **2k. Detailed knowledge of the monitoring devices and interpretation of the information provided by the monitors**

**2k. i. Clinical observation** *Continuous visual bedside observation of the patient represents the basic level of clinical monitoring during and after any procedural sedation (very good consensus: level of evidence B: grade of recommendation strong)*

Standard monitoring parameters [non-invasive BP (NIBP), pulse oximetry, ECG and capnography] are analysed separately in this section but their use during PSA should be considered mandatory. Given the rapid changes caused by the administration of sedative medications combined with analgesic drugs, it is important to have a continuous assessment of the levels of sedation that can vary during the procedure. This requires a

combination of clinical observation and monitoring.<sup>175,176</sup> The depth of sedation should be assessed periodically throughout a procedure by using one of these scales or by assessing responsiveness to verbal and tactile stimulation.<sup>177–179</sup> During procedures where a verbal response is not possible (e.g. oral surgery, upper endoscopy), the patient has to demonstrate his/her level of consciousness, such as by squeezing the hand in response to commands or a tactile stimulus. This response suggests that the patient will be able to control his airway and take deep breaths if necessary, corresponding to a state of moderate sedation. Note that a response limited to reflex withdrawal from a painful stimulus is not considered a purposeful response and thus represents a state of deep sedation or general anaesthesia.

**2k. ii and iii. Non-invasive blood pressure and ECG: intermittent non-invasive measurements of blood pressure and continuous ECG monitoring are considered mandatory in all patients undergoing procedural sedation (very good consensus: level of evidence B: grade of recommendation strong)**

Intermittent frequent measurements of NIBP at least every 5 min although such monitoring could interfere with the procedure<sup>180</sup> and continuous ECG monitoring are both considered mandatory during anaesthetic procedures including PSA. This statement is supported by the ESA/EBA taskforce and non-randomised control trials (non-RCTs) publications.<sup>181</sup> The importance of monitoring these parameters is supported by the fact that significant hypoxia and cardiac arrhythmias have been reported to be associated with upper gastrointestinal endoscopy with or without sedation. These events have been proposed to be associated with age and comorbidity of the patient, the extent and duration of the procedure, and the experience of the endoscopist.<sup>182</sup> Pulse rate and SBP have also both been reported to increase upon pharyngeal introduction of an endoscope.<sup>183</sup>

**2k. iv. Pulse oximetry: the most important device for clinical bedside monitoring: should be used in all patients undergoing procedural sedation (very good consensus: level of evidence B: grade of recommendation strong)**

As already mentioned above, continuous clinical observation of the patient should be the basic level of clinical monitoring in any patient subjected to PSA. Pulse oximetry, providing transcutaneous values of haemoglobin oxygenation (SpO<sub>2</sub>), should be used as a minimum standard for continuous monitoring of all patients undergoing procedural sedation. Not using pulse oximetry during PSA cannot be considered ethically acceptable. Continuous supply of oxygen and monitoring with pulse oximetry are mandatory to minimise the risk of, and rapidly manage, hypoxaemia.<sup>184,185</sup> Today, pulse oximetry is the standard for monitoring of severely ill or injured patients

in perioperative, intensive care and emergency medicine.<sup>186,187</sup> Pulse oximetry enhances patient safety by detecting hypoxaemia earlier and more reliably than other methods.<sup>186,188</sup> The sites most commonly used for detection (finger, toe, ear) have similar accuracy.<sup>187</sup> If available, the variable pitch ‘beep,’ which gives a continuous audible indication of the oxygen saturation reading, may be helpful. It is recommended to measure SpO<sub>2</sub> before starting PSA, when the patient is breathing room air, to know the patient’s baseline SpO<sub>2</sub> and to know which value should be aimed for during the recovery period. However, when using pulse oximetry, it should be taken into account that some influencing factors may lead to false measurements or a delayed display of desaturation or re-saturation. Changes in measurement kinetics or perfusion can lead to aberration of the pulse wave signal with deviations in accuracy and precision,<sup>188,189</sup> for example in hypotension,<sup>189</sup> or when nail polish<sup>190</sup> or acrylic finger nails<sup>191</sup> are used. Pulse oximetry measures oxygenation only but does not allow the evaluation of alveolar ventilation once supplemental oxygen is given to the patient.<sup>184</sup> Therefore, additional monitoring should be used to ensure appropriate respiratory function.

**2k. v. Capnography: by facilitating early detection of ventilation problems: should be used in all patients undergoing procedural sedation (very good consensus: level of evidence A: grade of recommendation strong)**

In addition to continuous monitoring by visual observation, NIBP, ECG and pulse oximetry, capnography should be used for continuous evaluation of ventilation.<sup>184</sup> It monitors the end-tidal concentration of carbon dioxide, which is in theory more sensitive to alveolar hypoventilation than SpO<sub>2</sub> and is standard monitoring for endotracheal intubation and ventilation in general anaesthesia.<sup>184,192</sup> Sidestream capnography can be measured with special nasal cannulae. Capnography has also been shown to provide earlier indications of apnoea than pulse oximetry.<sup>184,193</sup> Other studies have shown interventions based on capnography compared with standard monitoring with a pulse oximeter result in fewer episodes of apnoea and hypoxaemia.<sup>194–196</sup> Capnography detected 54 episodes of apnoea, and pulse oximetry 27 of them, in 28 of 49 patients subjected to procedural sedation for upper gastrointestinal endoscopy.<sup>193</sup> The addition of capnography to standard monitoring for propofol sedation in adult emergency care reduced, and improved early detection of, hypoxic events.<sup>197</sup> Simultaneous use of other techniques for carbon dioxide measurement (arterial blood gas analysis, transcutaneous measurement) can enhance the validity of capnographic measurements.<sup>198</sup>

A recent meta-analysis<sup>199</sup> supported the use of capnography during PSA concluding that episodes of respiratory depression were 17.6-times more likely to be detected by capnography compared with standard monitoring. Given this evidence in the literature, the ASA and the Academy of

Medical Royal Colleges included capnography in the basic monitoring standards whenever the patient has to undergo moderate or deep sedation.<sup>175,200</sup>

**2k. vi. Processed electroencephalogram monitors might be considered for monitoring of procedural sedation: particularly when using propofol (good consensus: level of evidence B: grade of recommendation weak)**

Some processed electroencephalogram monitors such as bispectral index (BIS) monitoring have been reported to minimise complications during sedation and to evaluate by objective measures the level of sedation.<sup>201,202</sup> In addition, BIS monitoring has been reported not to improve oxygenation or reduce cardiopulmonary complications,<sup>203</sup> and no clinical role of this kind of monitoring has been found during sedation for endoscopic procedures.<sup>204</sup> Nevertheless, BIS monitoring during procedural sedation with propofol has been reported to be associated with higher satisfaction among patients and endoscopists,<sup>204,205</sup> and to enable more effective titration and shorter procedures of sedation.<sup>206</sup> Altogether, available results on the use of BIS monitoring for procedural sedation remain controversial.

Clinical data on other cerebral monitoring methods [e.g. spectral entropy, Narcotrend, MT MonitorTechnik GMBH & CO, Hannover, Germany and Sedline, Masimo, Irvine (CA) USA] are rare. The scarce results indicate that they are utilised as monitors mainly to determine the depth of sedation during a propofol-based sedation.<sup>207</sup> Clinical assessment and Narcotrend-guided sedation using propofol for deep sedation demonstrated comparable propofol dose and recovery time.<sup>208</sup> Both monitoring systems were equally well tolerated and effective. However, the Narcotrend-guided sedation showed less haemodynamic changes and fewer complications compared with the clinical assessment-guided sedation.<sup>208</sup> Evidence supporting the use of these devices during PSA is supported by a limited number of studies.

**2l. Knowledge of the major type of complications and their management**

Procedural sedation analgesia can be the cause of a wide range of complications that can happen during or after the procedure. These range from mild to life-threatening events that need early and proper recognition and management by the clinician involved in the administration of the PSA (very good consensus – level of evidence B – GoR strong).

Even best practice may result in unavoidable complications. Relevant problems after PSA<sup>92,209–217</sup> include the following:

**2l.i. Respiratory depression**

Respiratory depression may present because of a decrease in depth and/or rate of ventilation and is attributed to

depression of respiratory control centres, which normally trigger breathing as carbon dioxide levels in the blood rise slightly above the normal threshold. All sedatives, opioids, and potent general anaesthesia inhalation agents have the potential to depress central hypercapnic and/or peripheral hypoxaemic drives, but this risk is minimal with moderate sedation, provided one uses conventional doses and monitors the patient appropriately. Nevertheless, one must be thoroughly skilled in managing respiratory depression in the event it should occur. Management of respiratory depression should commence with standard airway support. Pharmacological reversal of the sedative agents is indicated but requires adequate training.

### 2l. ii. Airway obstruction

Airway obstruction must be distinguished from respiratory depression. Although obstruction may result in hypoventilation, the patient's actual drive to ventilate (breathe) may or may not be obtunded. Upper airway obstruction may be attributed to anatomical structures or foreign material, both of which are addressed during the initial 'airway patency' portion of the primary assessment. When these procedures fail to establish patency, pathological causes of obstruction must be considered, namely laryngospasm or laryngeal oedema. These events can be distinguished visually by those trained in direct laryngoscopy, but otherwise the distinction is made empirically.

### 2l. iii. Arterial hypotension

Numerical values that change significantly from baseline should alert the clinician, but evaluation of skin colour changes and patient's consciousness can guide the clinician to maintain an adequate value of blood perfusion. In general, a SBP of 90 mmHg should sustain mean arterial pressure sufficiently to perfuse tissues in the recumbent patient.

### 2l. iv. Hypertension

'Hypertensive crisis' is the conventional term for sudden elevations in DBP to at least 120 mmHg. A hypertensive crisis is regarded as an 'urgency' if the patient remains asymptomatic and an 'emergency' if signs or symptoms are present, such as chest pain, headache or visual disturbances.

### 2l. v. Chest pain

Angina/myocardial infarction.

### 2l. vi. Cardiac arrest

### 2l. vii. Allergic reactions

The spectrum of allergic reactions can range from a minor local reaction to more severe anaphylactic reactions. The diagnosis of anaphylactic reaction is not always easy to establish. Anaphylactic reactions can present with mild dyspnoea in mild cases or lead to

hypotension and shock in severe cases. When a life-threatening anaphylactic reaction does occur, it simulates an acute cardiac, respiratory and metabolic crisis and requires urgent acute critical care. Treatment for anaphylactic reactions includes the discontinuation of the suspected allergen, airway management, fluid resuscitation, antihistamine drugs, hydrocortisone and epinephrine.

### 2l. viii. Other rare and minor problems include:

- (1) Vasovagal reactions
- (2) Arrhythmia
- (3) Pain and stress in patients
- (4) Hallucinations
- (5) Nausea and vomiting are common side-effects of opioids. In addition, the over distension of the stomach or colonic loop can produce nausea and vomiting after the endoscopic procedure.
- (6) Hypersalivation

## 2m. Knowledge of the interventions that may be used if required

### 2m. i. Use of supplemental oxygen

*Supplemental oxygen should be available whenever PSA is started and it can be administered to prevent hypoxia, especially in long procedures or whenever a hypoxic period is anticipated (good consensus: level of evidence B: GoR strong).*

There is still a debate on the use of supplemental oxygen during PSA<sup>218–220</sup> to reduce the incidence of hypoxaemia. The best evidence supporting the use of oxygen is a double blind, randomised trial of adults undergoing PSA with propofol<sup>218</sup> in which episodes of hypoxia (SpO<sub>2</sub> < 93%) lasting longer than 15 s occurred significantly more often (41%) among the 58 patients given compressed air by face mask compared with the 59 patients given high-flow oxygen (19%) using the same delivery system [difference 23%; (95% confidence interval: 6 to 38%)]. However, the clinical significance of such transient episodes of hypoxaemia remains debatable. Several observational studies have found that supplemental oxygen at lower concentrations does not reliably prevent hypoxaemia during PSA<sup>221,222</sup> and delays the detection of respiratory depression in patients without EtCO<sub>2</sub> monitors, as SpO<sub>2</sub> levels may not fall until a prolonged period of hypoventilation or apnoea has occurred.<sup>223,224</sup>

### 2m. ii. Haemodynamic support (outside cardiopulmonary resuscitation)

*Haemodynamic support in case of hypotension/hypertension or any cardiac arrhythmia associated with PSA should be initiated immediately to reduce the risk for a life-threatening condition. In case of major cardiac events, a cardiologist*

*should be consulted as soon as possible (moderate consensus: level of evidence N/A: GoR weak).*

### 3. How should recovery after procedural sedation and analgesia be managed?

**Patients must be monitored in a recovery room for at least 30 min after procedural sedation and analgesia (good consensus: level of evidence B: grade of recommendation strong)**

As patients may deteriorate considerably after procedural sedation, sufficient monitoring is essential, but there is no clear evidence on the way they should be monitored after procedural sedation. Although there is no clear evidence on who should monitor patients and how long patients should be monitored, from a practical point of view, post-sedation monitoring (with at least NIBP, ECG and pulse oximetry) is essential to supplement continuous visual observation by an experienced trained nurse. No clear recommendation can be given on whether recovery should take place in a separate room or in the sedation area, but monitoring for at least 30 min after procedural sedation is considered to be adequate.<sup>225</sup>

The basic criteria for suitability of a patient for discharge after PSA include:

- (1) Low-risk procedure with no need to monitor postoperative complications
- (2) Mental status and physiological signs should be returned to the baseline values and the patient should be able to take care of him/herself or just with minimal help
- (3) Postoperative symptoms such as pain, nausea and dizziness should be well tolerated
- (4) A reliable person should be always present with the patient to help him/her in the first hours after discharge.

Discharge criteria should be designed to minimise the risk for cardiorespiratory depression after patients are released from observation by trained personnel. Some discharge scores have been used successfully before to assess the patient after PSA and allow for an earlier discharge after colonoscopy.<sup>226,227</sup> It has also been suggested that patients are ready for discharge when they have reached their 'neuromuscular and cognitive pre-procedure baseline'.<sup>225</sup> To check discharge criteria in patients after PSA, the ALDRETE score seems to be feasible.<sup>228</sup>

Clear written discharge instructions should be given to the patient and to the patient's caregiver, who needs to accompany the patient after discharge. The clinician discharging the patient needs to explain the postoperative plan, which problems can arise and how to solve them and when the patient can return to normal activity. A follow-up should be offered to the patient in case he/she

could experience problems after having been discharged home.

### 4. Who should evaluate non-anaesthesia personnel and according to what criteria to establish they are adequately trained to perform procedural sedation and analgesia?

Anaesthesiologists (both anaesthesiologists and anaesthesia nurses in some countries) are the main specialists involved in PSA, and they are able to manage patients at various levels of sedation and general anaesthesia while mastering upper airways, ventilation and circulation. This taskforce suggests that, whenever PSA is provided by non-anaesthesiologists, the different national societies and health authorities have to consider a proper training of these clinicians in delivering well tolerated PSA. The training should be organised and provided by anaesthesia departments. An objective scoring system, for example the Global Rating Scale (Appendix 2 – Supplemental Digital File, <http://links.lww.com/EJA/A126>) suggested in these guidelines, should be considered to confirm individual proficiency for provision of PSA independently (good consensus – level of evidence N/A – GoR strong).

### 5. Gaps in evidence and future research

There are still grey areas not supported by strong evidence from RCTs or prospective observational studies. For some topics, such as monitoring, the lack of evidence is balanced by common sense as the advent of advanced monitoring such as peripheral oxygen saturation has dramatically improved safety by earlier detection of episodes of hypoventilation. The use of processed EEGs could lead in the future to the use of automatic closed-loop systems. The real gap in the evidence is represented by the training required to ensure that non-anaesthesiologist clinicians achieve and maintain competence in providing well tolerated PSA.<sup>229</sup> PSA is still associated with both predictable and unpredictable adverse events and complications and so the clinician involved in the management of PSA must have the skills to manage the whole process and its side-effects. Quality control studies are necessary to evaluate safety, complications and risk factors to allow each centre to evaluate its performance (benchmarking) as a basis for quality improvement.

### Summary and conclusion

PSA is a frequent practice in hospital and office-based facilities. In the near future, there will be an increasing number of requests for diagnostic/therapeutic interventions requiring PSA. An adequate evaluation of the patient is mandatory to screen for risk factors for possible complications related to the administration of drugs that alter the level of consciousness and can lead to adverse events. The healthcare provider involved in PSA needs a specific training and advanced skills in managing the airway and administering emergency drugs in case this

should be necessary. There is an on-going debate on whether the management of PSA should be centralised in the anaesthesia department. The role of anaesthesiologists should be maintained to coordinate and supervise PSA activities and training to maintain the highest levels of safety.

### Acknowledgements relating to this article

Assistance with the guidelines: none.

Financial support and sponsorship: none.

Conflicts of interest: ML received honoraria from Masimo (Irvine, California, USA); EDR received honoraria from Masimo (Irvine, California, USA) and MSD; DL has received grants and funding from LFB (France), Baxter International (USA), and Fresenius Kabi (Germany), and has received speaker's fees of Masimo, Medtronic, Edwards Laboratories, and Orion Pharma; MMRFS has received grants and funding from The Medicines Company (Parsippany, New Jersey, USA), Masimo (Irvine, California, USA), Fresenius (Bad Homburg, Germany), Dräger (Lübeck, Germany), Acacia Design (Maastricht, The Netherlands), and Medtronic (Dublin, Ireland) and honoraria from The Medicines Company (Parsippany, New Jersey, USA), Masimo (Irvine, California, USA), Fresenius (Bad Homburg, Germany), Baxter (Deerfield, Illinois, USA), Medtronic (Dublin, Ireland) and Demed Medical (Temse, Belgium). TFB has received honoraria for lectures from MSD.

Comments from the Editor: this guidelines article was checked by the editors but was not sent for additional, external peer review. FV and TFB are Associate Editors of the *European Journal of Anaesthesiology*.

### References

- De Robertis E, Longrois D. To streamline the guideline challenge: the European Society of Anaesthesiology policy on guidelines development. *Eur J Anaesthesiol* 2016; **33**:794–799.
- American Society of Anesthesiologists. Practice guidelines for sedation and analgesia by nonanesthesiologists. *Anesthesiology* 2002; **96**:1004.
- Department of Health and Human Services. Centers for Medicare and Medicaid Services Revised. Hospital Anesthesia Services Interpretive Guidelines – State Operations Manual (SOM) Appendix A Ref: S&C-10-09-Hospital. 2011. Available at: [https://www.cms.gov/SurveyCertificationGenInfo/downloads/SCLEt-ter10\\_09.pdf](https://www.cms.gov/SurveyCertificationGenInfo/downloads/SCLEt-ter10_09.pdf). [Accessed 25 August 2016]
- Sury M, Bullock I, Rabar S, et al. Sedation for diagnostic and therapeutic procedures in children and young people: summary of NICE guidance. *Brit Med J* 2010; **341**:c6819.
- Vargo JJ, Cohen LB, Rex DK, et al. Position statement: nonanesthesiologist administration of propofol for GI endoscopy. *Gastrointest Endosc* 2009; **70**:1053–1059.
- Bhananker SM, Posner KL, Cheney FW, et al. Injury and liability associated with monitored anesthesia care: a closed claims analysis. *Anesthesiology* 2006; **104**:228–234.
- Metzner J, Posner K, Lam M, et al. Closed claims' analysis. *Best Pract Res Clin Anaesthesiol* 2011; **25**:263–276.
- Mellin-Olsen J, Staender S, Whitaker DK, et al. The Helsinki declaration on patient safety in anaesthesiology. *Eur J Anaesthesiol* 2010; **27**:592–597.
- Green SM, Krauss B. Procedural sedation terminology: moving beyond 'conscious sedation'. *Ann Emerg Med* 2002; **39**:433.
- Commission The Joint. 2016. [https://www.jointcommission.org/standards\\_information/jcfaqdetails.aspx?StandardsFaqlD=1240&ProgramID=46](https://www.jointcommission.org/standards_information/jcfaqdetails.aspx?StandardsFaqlD=1240&ProgramID=46). [Accessed 25 August 2016]
- Knape H, Adriaansen H, van Aken H, et al. Guidelines for sedation and/or analgesia by nonanaesthesiology doctors. *Eur J Anaesthesiol* 2007; **24**:563–567.
- American Society of Anesthesiologists. *Continuum of depth of sedation: definition of general anesthesia and levels of sedation/analgesia*. 2007; Available at <http://www.asahq.org/For-Healthcare>. [27 October 2004].
- Brozek N, Akl EA, Jaeschke R, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. *Allergy* 2009; **64**:1109–1116.
- Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011; **64**:383–394.
- Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol* 2011; **64**:395–400.
- Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol* 2011; **64**:401–406.
- Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence – study limitations (risk of bias). *J Clin Epidemiol* 2011; **64**:407–415.
- Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence – publication bias. *J Clin Epidemiol* 2011; **64**:1277–1282.
- Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 6. Rating the quality of evidence – imprecision. *J Clin Epidemiol* 2011; **64**:1283–1293.
- Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence – inconsistency. *J Clin Epidemiol* 2011; **64**:1294–1302.
- Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence – indirectness. *J Clin Epidemiol* 2011; **64**:1303–1310.
- Guyatt GH, Oxman AD, Sultan S, et al. GRADE guidelines: 9. Rating up the quality of evidence. *J Clin Epidemiol* 2011; **64**:1311–1316.
- Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. *J Clin Epidemiol* 2011; **64**:380–382.
- Guyatt G, Rennie D, Meade M. *Users' guides to the medical literature: a manual for evidence-based clinical practice*. New York: McGraw-Hill; 2008.
- Guyatt G, Rennie D, Meade M, et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *Brit Med J* 2008; **336**:924–926.
- Fitch K, Bernstein SJ, Aguilar MD, et al. *The RAND/UCLA appropriateness method user's manual*. Santa Monica, CA: RAND Corporation; 2001; Available at: [http://www.rand.org/pubs/monograph\\_reports/MR1269.html](http://www.rand.org/pubs/monograph_reports/MR1269.html). [Accessed 14 July 2017].
- González N, Quintana JM, Lacalle JR, et al. Review of the utilization of the RAND appropriateness method in the biomedical literature (1999–2004). *Gac Sanit* 2009; **23**:232–237.
- Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: Cardiovascular Assessment and Management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). *Eur J Anaesthesiol* 2014; **31**:517–573.
- Mangano DT. Perioperative medicine: NHLBI working group deliberations and recommendations. *J Cardiothorac Vasc Anesth* 2004; **18**:1–6.
- Wirhlin DJ, Cambria RP. Surgery-specific considerations in the cardiac patient undergoing noncardiac surgery. *Prog Cardiovasc Dis* 1998; **40**:453–468.
- Gupta PK, Gupta H, Sundaram A, et al. Development and validation of a risk calculator for prediction of cardiac risk after surgery. *Circulation* 2011; **124**:381–387.
- Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation* 1999; **100**:1043–1049.
- Conway A, Rolley J, Page K, et al. Issues and challenges associated with nurse-administered procedural sedation and analgesia in the cardiac catheterisation laboratory: a qualitative study. *J Clin Nurs* 2014; **23**:374–384.
- Deftereos S, Giannopoulos G, Raisakis K, et al. Moderate procedural sedation and opioid analgesia during transradial coronary interventions to prevent spasm: a prospective randomized study. *JACC Cardiovasc Interv* 2013; **6**:267–273.
- Lewis SR, Nicholson A, Reed SS, et al. Anaesthetic and sedative agents used for electrical cardioversion. *Cochrane Database Syst Rev* 2015;CD010824.
- Sayfo S, Vakil KP, Alqaqa'a A, et al. A retrospective analysis of proceduralist-directed, nurse-administered propofol sedation for implantable cardioverter-defibrillator procedures. *Heart Rhythm* 2012; **9**:342–346.

- 37 Guarracino F, Covello RD, Landoni G, *et al.* Anesthetic management of transcatheter aortic valve implantation with transaxillary approach. *J Cardiothorac Vasc Anesth* 2011; **25**:437–443.
- 38 Mester R, Easley R, Brady K, *et al.* Monitored anesthesia care with a combination of ketamine and dexmedetomidine during cardiac catheterization. *Am J Therapeutics* 2008; **15**:24–30.
- 39 Thimmarayappa A, Chandrasekaran N, Jagadeesh AM, *et al.* Pediatric cardiac catheterization procedure with dexmedetomidine sedation: radiographic airway patency assessment. *Ann Card Anaesth* 2015; **18**:29–33.
- 40 Lichtenstein DR, Jagannath S, Baron TH, *et al.*, Committee Standards of Practice. Sedation and anesthesia in GI endoscopy. *Gastrointest Endosc* 2008; **68**:205–216.
- 41 Roy RC. The role of the anesthesiologist in the GI endoscopy unit. *Gastroenterol Hepatol* 2010; **6**:90–99.
- 42 Hillman DR, Loadsman JA, Platt PR, *et al.* Obstructive sleep apnea and anesthesia. *Sleep Med Rev* 2004; **8**:459–471.
- 43 Netzer NC, Stoohs RC, Netzer CM, *et al.* Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. *Ann Intern Med* 1999; **131**:485–491.
- 44 Kim GH, Lee JJ, Choi SJ, *et al.* Clinical predictors of apnoea–hypopnoea during propofol sedation in patients undergoing spinal anaesthesia. *Anaesthesia* 2012; **67**:755–759.
- 45 Adler D, Kawa C, Hilden K, *et al.* Nurse administered propofol sedation is safe for patients with obstructive sleep apnea undergoing routine endoscopy: a pilot study. *Dig Dis Sci* 2011; **56**:2666–2671.
- 46 Gill J, Vidyarthi G, Kulkarni P, *et al.* Safety of conscious sedation in patients with sleep apnea in a veteran population. *South Med J* 2011; **104**:185–188.
- 47 Khiani V, Salah W, Maimone S, *et al.* Sedation during endoscopy for patients at risk of obstructive sleep apnea. *Gastrointest Endosc* 2009; **70**:1116–1120.
- 48 Mador MJ, Nadler J, Mreyoud A, *et al.* Do patients at risk of sleep apnea have an increased risk of cardio-respiratory complications during endoscopic procedures? *Sleep Breath* 2012; **16**:609–615.
- 49 Cote GA, Hovis RM, Ansstas MA, *et al.* Incidence of sedation-related complications with propofol use during advanced endoscopic procedures. *Clin Gastroenterol Hepatol* 2010; **8**:137–142.
- 50 Wu W, Chen Q, Zhang LC, *et al.* Dexmedetomidine versus midazolam for sedation in upper gastrointestinal endoscopy. *J Int Med Res* 2014; **42**:516–522.
- 51 Jain S, Dhand R. Perioperative treatment of patients with obstructive sleep apnea. *Cur Opin Pulm Med* 2004; **10**:482–488.
- 52 Kress JP, Pohlman AS, Alverdy J, *et al.* The impact of morbid obesity on oxygen cost of breathing (VO<sub>2</sub>RESP). *Am J Respir Crit Care Med* 1999; **160**:883–886.
- 53 Lemzye M, Mallat J, Duhamel A, *et al.* Effects of sitting position and applied positive end-expiratory pressure on respiratory mechanics of critically ill obese patients receiving mechanical ventilation. *Crit Care Med* 2013; **41**:2592.
- 54 Welliver M, Bednarzyk M. Sedation considerations for the nonintubated obese patient in critical care. *Crit Care Nurs Clin North Am* 2009; **21**:341–352.
- 55 Isono S. Obstructive sleep apnea of obese adults: pathophysiology and perioperative airway management. *Anesthesiology* 2009; **110**:908–921.
- 56 Harris AT, Morell D, Bajaj Y, *et al.* A discussion of airway and respiratory complications along with general considerations in obese patients. *Int J Clin Pract* 2010; **64**:802–806.
- 57 Reinius H, Jonsson L, Gustafsson S, *et al.* Prevention of atelectasis in morbidly obese patients during general anesthesia and paralysis: a computerized tomography study. *Anesthesiology* 2009; **111**:979–987.
- 58 Arnoldo BD, Purdue GF, Kowalske K, *et al.* Electrical injuries: a 20-year review. *J Burn Care Rehabil* 2004; **25**:479–484.
- 59 Corso RM, Piraccini E, Agnoletti V, *et al.* Clinical use of the STOP-BANG questionnaire in patients undergoing sedation for endoscopic procedures. *Minerva Anestesiol* 2012; **78**:109–110.
- 60 Aantaa R, Tonner P, Conti G, *et al.* Sedation options for the morbidly obese intensive care unit patient: a concise survey and an agenda for development. *Multidiscip Respir Med* 2015; **101**:8.
- 61 Adams JP, Murphy PG. Obesity in anaesthesia and intensive care. *Br J Anaesth* 2000; **85**:91–108.
- 62 Lee SM, Kim GH, Lee JJ. Does propofol and alfentanil-induced sedation cause periodic apnoea in chronic renal failure patients? *Int J Clin Pract* 2010; **64**:1–5.
- 63 McCarley P, Wingard RL, Shyr Y, *et al.* Vascular access blood flow monitoring reduces access morbidity and costs. *Kidney Int* 2001; **60**:1164–1172.
- 64 Bergese SD, Bender SP, McSweeney TD, *et al.* A comparative study of dexmedetomidine with midazolam and midazolam alone for sedation during elective awake fiberoptic intubation. *J Clin Anesth* 2010; **22**:35–40.
- 65 Dean M. Opioids in renal failure and dialysis patients. *J Pain Symptom Manage* 2004; **28**:497–504.
- 66 Hohne C, Donaubauber B, Kaisers U. Opioids during anesthesia in liver and renal failure. *Anaesthesist* 2004; **53**:291–303.
- 67 Vinik HR, Reves JG, Greenblatt DJ, *et al.* The pharmacokinetics of midazolam in chronic renal failure patients. *Anesthesiology* 1983; **59**:390–394.
- 68 Niscola P, Scaramucci L, Vischini G, *et al.* The use of major analgetics in patients with renal dysfunction. *Curr Drug Targets* 2010; **11**:752–758.
- 69 Bailey PL, Pace NL, Ashburn MA, *et al.* Frequent hypoxemia and apnea after sedation with midazolam and fentanyl. *Anesthesiology* 1990; **73**:826–830.
- 70 Kamath PS, Wiesner RH, Malinchoc M, *et al.* A model to predict survival in patients with end-stage liver disease. *Hepatology* 2001; **33**:464.
- 71 Jensen DM. Endoscopic screening for varices in cirrhosis: findings, implications and outcomes. *Gastroenterology* 2002; **122**:1620–1630.
- 72 Thuluvath PJ. Toward safer sedation in patients with cirrhosis: have we done enough? *Gastrointest Endosc* 2009; **70**:269–277.
- 73 Allonen H, Zeigler G, Klotz U. Midazolam kinetics. *Clin Pharmacol Ther* 1981; **30**:653–661.
- 74 Daneshmend TK, Bell GD, Logan RF. Sedation for upper gastrointestinal endoscopy: results of a nationwide survey. *Gut* 1991; **32**:12–15.
- 75 Minuk GY, Shaffer E, Thomson A. *Modern concepts in gastroenterology. Vol 2.* New York: Plenum; 1989; 89–107.
- 76 Smith MT, Eadie MJ, Brophy TO. The pharmacokinetics of midazolam in man. *Eur J Clin Pharmacol* 1981; **19**:271–278.
- 77 Assy N, Rosser B, Grahame G, *et al.* Risk of sedation for upper GI endoscopy exacerbating subclinical hepatic encephalopathy in patients with cirrhosis. *Gastrointest Endosc* 1999; **49**:690–694.
- 78 Vasudevan AE, Goh KL, Bulgiba AM. Impairment of psychomotor responses after conscious sedation in cirrhotic patients undergoing therapeutic upper GI endoscopy. *Am J Gastroenterol* 2002; **97**:1717–1721.
- 79 Agrawal A, Sharma BC, Sharma P, *et al.* Randomized controlled trial for endoscopy with propofol versus midazolam on psychometric tests and critical flicker frequency in people with cirrhosis. *Gastroent Hepat* 2012; **27**:1726–1732.
- 80 Amorós A, Aparicio J, Garmendia M, *et al.* Deep sedation with propofol does not precipitate hepatic encephalopathy during elective upper endoscopy. *Gastrointest Endosc* 2009; **70**:262.
- 81 Correia LM, Bonilha DC, Gomes GF, *et al.* Sedation during upper GI endoscopy in cirrhotic outpatients: a randomized, controlled trial comparing propofol and fentanyl with midazolam and fentanyl. *Gastrointest Endosc* 2011; **73**:45–51.
- 82 MacGilchrist AJ, Birnie GG, Cook A, *et al.* Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. *Gut* 1986; **27**:190–195.
- 83 Rinetti M, Ascalone V, Zinelli L, *et al.* A pharmacokinetic study on midazolam in compensated liver cirrhosis. *Int J Clin Pharmacol Res* 1985; **5**:405–411.
- 84 Riphaut A, Lechowicz I, Frenz MB, *et al.* Propofol sedation for upper gastrointestinal endoscopy in patients with liver cirrhosis as an alternative to midazolam to avoid acute deterioration of minimal encephalopathy: a randomized, controlled study. *Scand J Gastroenterol* 2009; **44**:1244–1251.
- 85 Servin F, Cockshott ID, Farinotti R, *et al.* Pharmacokinetics of propofol infusions in patients with cirrhosis. *Brit J Anaesth* 1990; **65**:177–183.
- 86 Sharma P, Singh S, Sharma BC, *et al.* Propofol sedation during endoscopy in patients with cirrhosis, and utility of psychometric tests and critical flicker frequency in assessment of recovery from sedation. *Endoscopy* 2011; **43**:400–405.
- 87 Horiuchi A, Nakayama Y, Hidaka N, *et al.* Low-dose propofol sedation for diagnostic esophagogastroduodenoscopy: results in 10,662 adults. *Am J Gastroenterol* 2009; **104**:1650–1655.
- 88 Ekstein M, Gavish D, Ezri T, *et al.* Monitored anesthesia care in the elderly. *Drugs Aging* 2008; **25**:477–500.
- 89 Travis A, Pievsky D, Saltzman J. Endoscopy in the elderly. *Am J Gastroenterol* 2012; **107**:1495–1501.
- 90 Fritz E, Kirchgatterer A, Hubner D, *et al.* ERCP is safe and effective in patients 80 years of age and older compared with younger patients. *Gastrointest Endosc* 2006; **64**:899–905.

- 91 Katsinelos P, Kountouras J, Chatzimavroudis G, *et al.* Outpatient therapeutic endoscopic retrograde cholangiopancreatography is safe in patients aged 80 years and older. *Endoscopy* 2011; **43**:128–133.
- 92 Salminen P, Grönroos JM. Anesthesiologist assistance in endoscopic retrograde cholangiopancreatography procedures in the elderly: is it worthwhile? *J Laparoendosc Adv Surg Tech A* 2011; **21**:517–519.
- 93 Attanasio A, Bedin M, Stocco S, *et al.* Clinical outcomes and complications of enteral nutrition among older adults. *Minerva Med* 2009; **100**:159–166.
- 94 Callahan CM, Haag KM, Weinberger M, *et al.* Outcomes of percutaneous endoscopic gastrostomy among older adults in a community setting. *J Am Geriatr Soc* 2000; **48**:1048–1054.
- 95 Clarke GA, Jacobson BC, Hammett RJ, *et al.* The indications, utilization and safety of gastrointestinal endoscopy in an extremely elderly patient cohort. *Endoscopy* 2001; **33**:580–584.
- 96 Lee TC, Huang SP, Yang JY, *et al.* Age is not a discriminating factor for outcomes of therapeutic upper gastrointestinal endoscopy. *Hepatogastroenterology* 2007; **54**:1319–1322.
- 97 Lockhart SP, Schofield PM, Gribble RJ, *et al.* Upper gastrointestinal endoscopy in the elderly. *Br Med J (Clin Res Ed)* 1985; **290**:283.
- 98 Martinez JF, Aparicio JR, Company L, *et al.* Safety of continuous propofol sedation for endoscopic procedures in elderly patients. *Rev Esp Enferm Dig* 2011; **103**:76–82.
- 99 Arora G, Mannalithara A, Singh G, *et al.* Risk of perforation from a colonoscopy in adults: a large population-based study. *Gastrointest Endosc* 2009; **69**:654–664.
- 100 Day LW, Inadomi JM, Samsouk S. Adverse events in elderly patients undergoing colonoscopy: a meta-analysis. *Gastroenterology* 2010; **138**:S126.
- 101 Lukens FJ, Loeb DS, Machicao VI, *et al.* Colonoscopy in octogenarians: a prospective outpatient study. *Am J Gastroenterol* 2002; **97**:1722–1725.
- 102 Riphaut A, Stergiou N, Wehrmann T. Sedation with propofol for routine ERCP in high-risk octogenarians: a randomized, controlled study. *Am J Gastroenterol* 2005; **100**:1957–1963.
- 103 Schilling D, Rosenbaum A, Schweizer S, *et al.* Sedation with propofol for interventional endoscopy by trained nurses in high-risk octogenarians: a prospective, randomized, controlled study. *Endoscopy* 2008; **41**:295–298.
- 104 Liu LL. Conscious sedation in the elderly. In: Wiener-Kronish JP, Gropper MA, editors. *Conscious sedation*. Philadelphia: Hanley & Belfus, Inc; 2001. pp. 105–117.
- 105 Schnider TW, Minto CF, Shafer SL, *et al.* The influence of age on propofol pharmacodynamics. *Anesthesiology* 1999; **90**:1502–1516.
- 106 Bell GD, Spickett GP, Reeve PA, *et al.* Intravenous midazolam for upper gastrointestinal endoscopy: a study of 800 consecutive cases relating dose to age and sex of patient. *Br J Clin Pharmacol* 1987; **23**:241–243.
- 107 Christe C, Janssens JP, Armenian B, *et al.* Midazolam sedation for upper gastrointestinal endoscopy in older persons: a randomized, double-blind, placebo-controlled study. *J Am Geriatr Soc* 2000; **48**:1398–1403.
- 108 Heuss LT, Schnieper P, Drewe J, *et al.* Conscious sedation with propofol in elderly patients: a prospective evaluation. *Aliment Pharmacol Ther* 2003; **17**:1493–1501.
- 109 Heuss L, Schnieper P, Drewe J, *et al.* Safety of propofol for conscious sedation during endoscopic procedures in high-risk patients – a prospective, controlled study. *Am Coll Gastroenterol* 2003; **98**:1751–1757.
- 110 Muller S, Prolla JC, Maguilnik I, *et al.* Predictive factors of oxygen desaturation of patient submitted to endoscopic retrograde cholangiopancreatography under conscious sedation. *Arch Gastroenterol* 2004; **41**:162–166.
- 111 Sarma VK, Nguyen CC, Crowell MD, *et al.* A national study of cardiopulmonary unplanned events after GI endoscopy. *Gastrointest Endosc* 2007; **66**:27–34.
- 112 Niklewski PJ, Phero JC, Martin JF, *et al.* A novel index of hypoxemia for assessment of risk during procedural sedation. *Anesth Analg* 2014; **119**:848–856.
- 113 Kheterpal S, Han R, Tremper KK, *et al.* Incidence and predictors of difficult and impossible mask ventilation. *Anesthesiology* 2006; **105**:885–891.
- 114 Kheterpal S, Martin L, Shanks AM, *et al.* Prediction and outcomes of impossible mask ventilation: a review of 50 000 anesthetics. *Anesthesiology* 2009; **110**:891–897.
- 115 Langeron O, Masso E, Huraux C, *et al.* Prediction of difficult mask ventilation. *Anesthesiology* 2000; **92**:1229–1236.
- 116 Bindra A, Prabhakar H, Singh GP, *et al.* Is the modified Mallampati test performed in supine position a reliable predictor of difficult tracheal intubation? *J Anesth* 2010; **24**:482–485.
- 117 El-Ganzouri AR, McCarthy RJ, Tuman KJ, *et al.* Preoperative airway assessment: predictive value of a multivariate risk index. *Anesth Analg* 1986; **82**:1197–1204.
- 118 Frerk C, Mitchell VS, McNarry AF, *et al.* Difficult Airway Society 2015 guidelines for management of unanticipated difficult intubation in adults. *Brit J Anaesth* 2015; **115**:827–848.
- 119 Mallampati S, Gatt S, Gugino L, *et al.* A clinical sign to predict difficult tracheal intubation: a prospective study. *Can Anaesth Soc J* 1985; **32**:429–434.
- 120 American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Practice Guidelines for Management of the Difficult Airway. An updated report by the American Society of Anesthesiologists Task Force on Management of the Difficult Airways. *Anesthesiology* 2013; **118**:251–270.
- 121 Goldberg ME, Norris MC, Larijani GE, *et al.* Preoxygenation in the morbidly obese: a comparison of two techniques. *Anesth Analg* 1989; **68**:520–522.
- 122 Lyons G. Failed intubation. Six years' experience in a teaching maternity unit. *Anaesthesia* 1985; **40**:759–762.
- 123 Norris MC, Dewan DM. Preoxygenation for cesarean section: a comparison of two techniques. *Anesthesiology* 1985; **62**:827–829.
- 124 Quan WL, Chia CK, Yim HB. Safety of endoscopic procedures during pregnancy. *Singapore Med J* 2006; **47**:525–528.
- 125 Bellolio MF, Gilani WI, Barrionuevo P, *et al.* Incidence of adverse events in adults undergoing procedural sedation in the emergency department: a systematic review and meta-analysis. *Acad Emerg Med* 2016; **23**:119–134.
- 126 Fisher L, Ormonde DG, Riley RH, *et al.* Endoscopic skills training in a simulated clinical setting. *Simul Healthc* 2010; **5**:232–237.
- 127 Deakin CD, Murphy D, Couzins M, *et al.* Does an advanced life support course give nonanaesthetists adequate skills to manage an airway? *Resuscitation* 2010; **81**:539–543.
- 128 Edwards JA, Kinsella J, Shaw A, *et al.* Sedation for oocyte retrieval using target controlled infusion of propofol and incremental alfentanil delivered by nonanaesthetists. *Anaesthesia* 2010; **65**:453–461.
- 129 Kuypers MI, Mencl F, Verhagen MF, *et al.* Safety and efficacy of procedural sedation with propofol in a country with a young emergency medicine training program. *Eur J Emerg Med* 2011; **18**:162–167.
- 130 Landham P, Butt U, Sanaullah A, *et al.* Sedation by surgeons: is patient safety being compromised by nonanaesthetists? *Br J Med Practition* 2011; **4**:a421.
- 131 Mazzon D, Germana' B, Poole D, *et al.* Conscious sedation during endoscopic retrograde colangiopancreatography: implementation of SIED-SIAARTI-ANOTE guidelines in Belluno hospital. *Minerva Anesthesiol* 2005; **71**:101–109.
- 132 Robbertze R, Posner KL, Domino KB. Closed claims review of anesthesia for procedures outside the operating room. *Curr Opin Anesthesiol* 2006; **19**:436–442.
- 133 Trummel J. Sedation for gastrointestinal endoscopy: the challenging landscape. *Curr Opin Anesthesiol* 2007; **20**:359–364.
- 134 Royal College of Anaesthetists. *UK Academy of Medical Royal Colleges and their Faculties. Implementing and ensuring safe sedation practice for healthcare procedures in adults. Report of an Intercollegiate working party chaired by the Royal College of Anaesthetists*. 2001; Available at: [http://www.rcoa.ac.uk/system/files/PUB-SafeSedPrac\\_1.pdf](http://www.rcoa.ac.uk/system/files/PUB-SafeSedPrac_1.pdf). [Accessed 14 July 2017].
- 135 DeJong A, Molinari N, Terzi N, *et al.* Early identification of patients at risk for difficult intubation in the intensive care unit: development and validation of the MACOCHA score in a multicenter cohort study. *Am J Respir Crit Care Med* 2013; **187**:832–839.
- 136 Alexander R, Moore C. The laryngeal mask airway and training in nasotracheal intubation. *Anaesthesia* 1993; **48**:350–351.
- 137 Konrad C, Schüpfer G, Wietlisbach M, *et al.* Learning manual skills in anesthesiology: is there a recommended number of cases for anesthetic procedures? *Anesth Analg* 1998; **86**:635–639.
- 138 Agostoni M, Fanti L, Gemma M, *et al.* Adverse events during monitored anesthesia care for GI endoscopy: an 8-year experience. *Gastrointest Endosc* 2011; **74**:266–275.
- 139 Macnab AJ, Levine M, Glick N, *et al.* A research tool for measurement of recovery from sedation: the Vancouver Sedative Recovery Scale. *J Pediatr Surg* 1991; **26**:1263–1267.
- 140 Malviya CS, Voepel-Lewis T, Tait AR, *et al.* Depth of sedation in children undergoing computed tomography: validity and reliability of the University of Michigan Sedation Scale (UMSS). *Brit J Anaesth* 2002; **88**:241–245.
- 141 Sinclair R, Faleiro R. Delayed recovery of consciousness after anaesthesia. *Continuing Educ Anaesth Crit Care Pain* 2006; **6**:114–118.
- 142 Ma I, Zalunardo N, Pachev G, *et al.* Comparing the use of global rating scale with checklists for the assessment of central venous catheterization skills using simulation. *Adv Health Sci Educ* 2012; **17**:457–470.



- 143 Tavares W, Boet S, Theriault R, *et al.* Global rating scale for the assessment of paramedic clinical competence. *Prehosp Emerg Care* 2013; **17**:57–67.
- 144 General Medical Council. *Consent: patients and doctors making decisions together*. London: General Medical Council; 2008.
- 145 Godwin SA, Caro DA, Wolf SJ, *et al.* Clinical policy: procedural sedation and analgesia in the emergency department. *Ann Emerg Med* 2005; **45**:177.
- 146 IV Procedural Sedation and Analgesia for Adults Standards NHMSFP – College of Physicians and Surgeons of British Columbia 2009. 2009. Available at <https://www.cpsbc.ca/files/pdf/NHMSFP-IV-Sedation-for-Adults-Standard.pdf>. [Accessed 14 July 2017]
- 147 Becker DE, Haas DA. Management of complications during moderate and deep sedation: respiratory and cardiovascular considerations. *Anesth Prog* 2007; **54**:59–68.
- 148 Miner JR, Burton JH. Clinical practice advisory: emergency department procedural sedation with propofol. *Ann Emerg Med* 2008; **50**:182–187.
- 149 Hansen TG. Sedative medications outside the operating room and the pharmacology of sedatives. *Curr Opin Anaesthesiol* 2015; **28**:446–452.
- 150 Lamperti M. Adult procedural sedation: an update. *Curr Opin Anaesthesiol* 2015; **28**:662–667.
- 151 Prescilla R, Mason KP. Recent advances and contributions to procedural sedation with considerations for the future. *Minerva Anesthesiol* 2014; **80**:844–855.
- 152 Krejcie TC, Avram MJ. When Duzitol does not do it all: the two sides of drug synergy. *Anesth Analg* 2011; **113**:441–443.
- 153 Hannam JA, Borrat X, Troconiz IF, *et al.* Modeling respiratory depression induced by remifentanyl and propofol during sedation and analgesia using a continuous noninvasive measurement of pCO<sub>2</sub>. *J Pharmacol Exp Ther* 2016; **356**:563–573.
- 154 LaPierre CD, Johnson KB, Randall BR, *et al.* An exploration of remifentanyl-propofol combinations that lead to a loss of response to esophageal instrumentation, a loss of responsiveness, and/or onset of intolerable ventilatory depression. *Anesth Analg* 2011; **113**:490–499.
- 155 Yoo H, Irola T, Vilo S, *et al.* Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects. *Eur J Clin Pharmacol* 2015; **71**:1197–1207.
- 156 Allen M, Leslie K, Hebbard G, *et al.* A randomized controlled trial of light versus deep propofol sedation for elective outpatient colonoscopy: recall, procedural conditions, and recovery. *Can J Anaesth* 2015; **62**:1169–1178.
- 157 Childers RE, Williams JL, Sonnenberg A. Practice patterns of sedation for colonoscopy. *Gastrointest Endosc* 2015; **82**:503–511.
- 158 Neuman G, Koren G. Safety of procedural sedation in pregnancy. *J Obstet Gynaecol Can* 2013; **35**:168–173.
- 159 Newstead B, Bradburn S, Appelboam A, *et al.* Propofol for adult procedural sedation in a UK emergency department: safety profile in 1008 cases. *Br J Anaesth* 2013; **111**:651–655.
- 160 Salukhe TV, Willems S, Drewitz I, *et al.* Propofol sedation administered by cardiologists without assisted ventilation for long cardiac interventions: an assessment of 1000 consecutive patients undergoing atrial fibrillation ablation. *Europace* 2012; **14**:325–330.
- 161 Wakai A, Blackburn C, McCabe A, *et al.* The use of propofol for procedural sedation in emergency departments. *Cochrane Database Syst Rev* 2015;CD007399.
- 162 Yan JW, McLeod SL, Iansavitchene A. Ketamine-propofol versus propofol alone for procedural sedation in the emergency department: a systematic review and meta-analysis. *Acad Emerg Med* 2015; **22**:1003–1013.
- 163 Vanluchene AL, Vereecke H, Thas O, *et al.* Spectral entropy as an electroencephalographic measure of anesthetic drug effect: a comparison with bispectral index and processed midlatency auditory evoked response. *Anesthesiology* 2004; **101**:34–42.
- 164 Bouillon T, Bruhn J, Radu-Radulescu L, *et al.* Mixed-effects modeling of the intrinsic ventilatory depressant potency of propofol in the nonsteady state. *Anesthesiology* 2004; **100**:240–250.
- 165 Bouillon TW, Bruhn J, Radulescu L, *et al.* Pharmacodynamic interaction between propofol and remifentanyl regarding hypnosis, tolerance of laryngoscopy, bispectral index, and electroencephalographic approximate entropy. *Anesthesiology* 2004; **100**:1353–1372.
- 166 Reves JG, Fragen RJ, Vinik HR, *et al.* Midazolam: pharmacology and uses. *Anesthesiology* 1985; **62**:310–324.
- 167 Smith I, White PF, Nathanson M, *et al.* Propofol: an update on its clinical use. *Anesthesiology* 1994; **81**:1005–1043.
- 168 Mion G, Villeveille T. Ketamine pharmacology: an update (pharmacodynamics, molecular aspects, recent findings). *CNS Neurosc Ther* 2013; **19**:370–380.
- 169 White PF, Way WL, Trevor AJ. Ketamine: its pharmacology and therapeutic uses. *Anesthesiology* 1982; **56**:119–136.
- 170 Lowenthal DT, Matzek KM, MacGregor TR. Clinical pharmacokinetics of clonidine. *Clin Pharmacokinet* 1988; **14**:287–310.
- 171 Venn RM, Karol MD, Grounds RM. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care. *Br J Anaesth* 2002; **88**:669–675.
- 172 Zhang F, Sun HR, Zheng ZB, *et al.* Dexmedetomidine versus midazolam for sedation during endoscopy: a meta-analysis. *Exp Ther Med* 2016; **11**:2519–2524.
- 173 Short TG, Hannam JA, Laurent S, *et al.* Refining target-controlled infusion: an assessment of pharmacodynamic target-controlled infusion of propofol and remifentanyl using a response surface model of their combined effects on bispectral index. *Anesth Analg* 2016; **122**:90–97.
- 174 Singh PM, Borle A, Goudra BG. Use of computer-assisted drug therapy outside the operating room. *Curr Opin Anaesthesiol* 2016; **29**:506–511.
- 175 American Society of Anesthesiologists. Standards for basic anesthetic monitoring. 2010. Available from: <http://www.asahq.org/For-Members/Clinical/Information/Standards/-Guidelines-and-Statements.aspx>. [Accessed 14 July 2017]
- 176 Eichhorn V, Henzler D, Murphy MF. Standardizing care and monitoring for anesthesia or procedural sedation delivered outside the operating room. *Curr Opin Anaesthesiol* 2010; **23**:494–499.
- 177 American Society of Anesthesiologists. Continuum of depth of sedation. 2014. Available from [http://www.asahq.org/for-members/~/\\_media/For%20Members/documents/Standards%20Guidelines%20Stmts/Continuum%20of%20Depth%20of%20Sedation.aspx](http://www.asahq.org/for-members/~/_media/For%20Members/documents/Standards%20Guidelines%20Stmts/Continuum%20of%20Depth%20of%20Sedation.aspx). [Accessed 14 July 2017]
- 178 Chernik DA, Gillings D, Laine H, *et al.* Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam. *J Clin Psychopharmacol* 1990; **10**:244–251.
- 179 Ramsay MA, Savege TM, Simpson BR, *et al.* Controlled sedation with alphaxalone–alphadolone. *Brit Med J* 1974; **2**:656–659.
- 180 American Society of Anesthesiologists. Standards for basic anesthetic monitoring 2015. 2015. Available at: <http://www.asahq.org/quality-and-practice-management/standards-and-guidelines>. [Accessed 14 July 2017]
- 181 Teague G. *Guidelines on safety and sedation during endoscopic procedures*. 2003; Available from: URL: <http://www.bsg.org.uk/clinical-guidelines/endoscopy/guidelines-on-safety-and-sedation-duringendoscopic-procedures.html>. [Accessed 14 July 2017].
- 182 Quine MA, Bell GD, McCloy RF, *et al.* Prospective audit of upper gastrointestinal endoscopy in two regions of England: safety, staffing and sedation methods. *Gut* 1995; **36**:462–467.
- 183 Murray AW, Morran CG, Kenny GNC, *et al.* Comparison of monitoring of arterial oxygen saturation, arterial pressure and the electrocardiogram. *Anaesthesia* 1991; **46**:181–184.
- 184 Arakawa H, Kaise M, Sumiyama K, *et al.* Does pulse oximetry accurately monitor a patient's ventilation during sedated endoscopy under oxygen supplementation? *Singapore Med J* 2013; **54**:212–215.
- 185 Sharma SK. The role of sedation and pulse oximetry during upper gastrointestinal endoscopy. *J Nepal Med Assoc* 2009; **48**:92–98.
- 186 Aoyagi T, Kishi M, Yamaguchi K, Watanabe S. Improvement of the earpiece oximeter. Abstracts of the 13th annual meeting of the Japanese Society of Medical Electronics and Biological Engineering. 1974:90–91 (Jap).
- 187 Hinkelbein J, Hose D, Fiedler F. Comparison of three different sensor sites for pulse oximetry in critically ill patients. *Int J Intensive Care* 2005; **12**:159–163.
- 188 Pedersen T, Moller AM, Pedersen BD. Pulse oximetry for perioperative monitoring: systematic review of randomized, controlled trials. *Anesth Analg* 2003; **96**:426–431.
- 189 Hinkelbein J, Genzwuerker HV, Fiedler F. Detection of a systolic pressure threshold for reliable readings in pulse oximetry. *Resuscitation* 2005; **64**:315–319.
- 190 Hinkelbein J, Genzwuerker HV, Sogl R, *et al.* Effect of nail polish on oxygen saturation as determined by pulse oximetry in critically ill patients. *Resuscitation* 2007; **72**:81–91.
- 191 Hinkelbein J, Koehler H, Genzwuerker HV, *et al.* Artificial acrylic finger nails may alter pulse oximetry measurement. *Resuscitation* 2007; **74**:75–82.
- 192 Waring JP, Baron TH, Hirota WK, *et al.* Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy. *Gastrointest Endosc* 2003; **58**:317–322.
- 193 Vargo JJ Jr, Zuccaro G, Dumot JA, *et al.* Automated graphic assessment of respiratory activity is superior to pulse oximetry and visual assessment for the detection of early respiratory depression during therapeutic upper endoscopy. *Gastrointest Endosc* 2002; **55**:826–831.
- 194 Beitz A, Riphaut A, Meining A, *et al.* Capnographic monitoring reduces the incidence of arterial oxygen desaturation and hypoxemia during propofol sedation for colonoscopy: a randomized, controlled study (ColoCap Study). *Am J Gastroenterol* 2012; **107**:1205–1212.

- 195 Cacho G, Pérez-Calle JL, Barbado A, *et al.* Capnography is superior to pulse oximetry for the detection of respiratory depression during colonoscopy. *Rev Esp Enferm Dig* 2010; **102**:86–89.
- 196 Qadeer MA, Vargo JJ, Dumot JA, *et al.* Capnographic monitoring of respiratory activity improves safety of sedation for endoscopic cholangiopancreatography and ultrasonography. *Gastroenterology* 2009; **136**:1568–1576.
- 197 Deitch K, Miner J, Chudnofsky CR, *et al.* Does end tidal CO<sub>2</sub> monitoring during emergency department procedural sedation and analgesia with propofol decrease the incidence of hypoxic events? A randomized, controlled trial. *Ann Emerg Med* 2010; **55**:258–264.
- 198 Spelten O, Warnecke T, Wetsch WA, *et al.* Dispatcher-assisted compression-only cardiopulmonary resuscitation provides best quality cardiopulmonary resuscitation by laypersons: a randomised controlled single-blinded manikin trial. *Eur J Anaesthesiol* 2015; **33**:575–580.
- 199 Waugh JB, Epps CA, Khodneva YA. Capnography enhances surveillance of respiratory events during procedural sedation: a meta-analysis. *J Clin Anesth* 2011; **23**:189–196.
- 200 Academy of Medical Royal Colleges. Safe sedation practice for healthcare procedures standards and guidance. 2013. Available from <http://www.rcoa.ac.uk/system/files/PUB-SafeSedPrac2013.pdf>. [Accessed 14 July 2017]
- 201 Bower AL, Ripepi A, Dilger J, *et al.* Bispectral index monitoring of sedation during endoscopy. *Gastrointest Endosc* 2000; **52**:192–196.
- 202 Kang KJ, Min BH, Lee MJ, *et al.* Efficacy of bispectral index monitoring for midazolam and meperidine induced sedation during endoscopic submucosal dissection: a prospective, randomized controlled study. *Gut* 2011; **5**:160–164.
- 203 von Delius S, Salletmaier H, Meining A, *et al.* Bispectral index monitoring of midazolam and propofol sedation during endoscopic retrograde cholangiopancreatography: a randomized clinical trial (the EndoBIS study). *Endoscopy* 2012; **44**:258–262.
- 204 Drake LM, Chen SC, Rex DK. Efficacy of bispectral monitoring as an adjunct to nurse-administered propofol sedation for colonoscopy: a randomized controlled trial. *Am J Gastroenterol* 2006; **101**:2003–2007.
- 205 Imagawa A, Fujiki S, Kawahara Y, *et al.* Satisfaction with bispectral index monitoring of propofol-mediated sedation during endoscopic submucosal dissection: a prospective, randomized study. *Endoscopy* 2008; **40**:905–909.
- 206 Bell JK, Laasch HU, Wilbraham L, *et al.* Bispectral index monitoring for conscious sedation in intervention: better, safer, faster. *Clinical Radiol* 2004; **59**:1106–1113.
- 207 Kwon MY, Lee SY, Kim TY, *et al.* Spectral entropy for assessing the depth of propofol sedation. *Korean J Anesthesiol* 2012; **62**:234–239.
- 208 Amornytin S, Chalayonnawin W, Kongphlay S. Deep sedation for endoscopic retrograde cholangiopancreatography: a comparison between clinical assessment and Narcotrend™ monitoring. *Med Devices (Auckl)* 2011; **4**:43–49.
- 209 Amornytin S. Sedation-related complications in gastrointestinal endoscopy. *World J Gastrointest Endosc* 2013; **5**:527–533.
- 210 Becke DE, Haas D. Management of complications during moderate and deep sedation: respiratory and cardiovascular considerations. *Anesth Prog* 2007; **54**:59–69.
- 211 Cheung KW, Watson ML, Field S, *et al.* Aspiration pneumonitis requiring intubation after procedural sedation and analgesia: a case report. *Ann Emerg Med* 2007; **49**:462–464.
- 212 Conway A, Page K, Rolley J, *et al.* Risk factors for impaired respiratory function during nurse-administered procedural sedation and analgesia in the cardiac catheterisation laboratory: a matched case-control study. *Eur J Cardiovasc Nurs* 2013; **12**:393–399.
- 213 Froehlich F, Gonvers JJ, Fried M. Conscious sedation, clinically relevant complications and monitoring of endoscopy: results of a nationwide survey in Switzerland. *Endoscopy* 1994; **26**:231–234.
- 214 Green SM, Krauss B. Pulmonary aspiration risk during emergency department procedural sedation – an examination of the role of fasting and sedation depth. *Acad Emerg Med* 2002; **9**:35–42.
- 215 Jacques KG, Dewar A, Gray A, *et al.* Procedural sedation and analgesia in a large UK Emergency Department: factors associated with complications. *Emerg Med J* 2011; **28**:1036–1040.
- 216 Miller MA, Levy P, Patel MM. Procedural sedation and analgesia in the emergency department: what are the risks? *Emerg Med Clin N Am* 2005; **23**:551–572.
- 217 Tobias JD, Leder M. Procedural sedation: a review of sedative agents, monitoring, and management of complications. *Saudi J Anaesth* 2011; **5**:395–410.
- 218 Deitch K, Chudnofsky CR, Dominici P, *et al.* The utility of high-flow oxygen during emergency department procedural sedation and analgesia with propofol: a randomized, controlled trial. *Ann Emerg Med* 2011; **58**:360.
- 219 Keidan I, Gravenstein D, Berkenstadt H, *et al.* Supplemental oxygen compromises the use of pulse oximetry for detection of apnea and hypoventilation during sedation in simulated pediatric patients. *Pediatrics* 2008; **122**:293–298.
- 220 Rozario L, Sloper D, Sheridan MJ. Supplemental oxygen during moderate sedation and the occurrence of clinically significant desaturation during endoscopic procedures. *Gastroenterol Nurs* 2008; **31**:281–285.
- 221 Deitch K, Chudnofsky CR, Dominici P. The utility of supplemental oxygen during emergency department procedural sedation and analgesia with midazolam and fentanyl: a randomized, controlled trial. *Ann Emerg Med* 2007; **49**:1–8.
- 222 Miner JR, Biros MH, Heegaard W, *et al.* Bispectral electroencephalographic analysis of patients undergoing procedural sedation in the emergency department. *Acad Emerg Med* 2003; **10**:638.
- 223 McQuillen KK, Steele DW. Capnography during sedation/analgesia in the pediatric emergency department. *Pediatr Emerg Care* 2000; **16**:401.
- 224 Miner JR, Heegaard W, Plummer D. End-tidal carbon dioxide monitoring during procedural sedation. *Acad Emerg Med* 2002; **9**:275.
- 225 Newman DH, Azer MM, Pitetti RD, *et al.* When is a patient safe for discharge after procedural sedation? The timing of adverse effect events in 1367 pediatric procedural sedations. *Ann Emerg Med* 2003; **42**:627.
- 226 Hickey N, O'Leary M, Falk V, *et al.* When is it safe to discharge patients following colonoscopy? Validation of the Aldrete score. Society of American Gastrointestinal and Endoscopic Surgeons Meeting P075; 2013. Available at <http://www.sages.org/meetings/annual-meeting/abstracts-archive/when-is-it-safe-to-discharge-patients-following-colonoscopy-validation-of-the-aldrete-score/>. [Accessed 14 July 2017]
- 227 Trevisani L, Cifalà V, Gilli G, *et al.* Post-anaesthetic discharge scoring system to assess patient recovery and discharge after colonoscopy. *World J Gastrointest Endosc* 2013; **5**:502–507.
- 228 Aldrete JA, Kroulik D. A postanesthetic recovery score. *Anesth Analg* 1970; **49**:924–934.
- 229 Cravero P, Beach ML, Blike GT, *et al.* Pediatric Sedation Research Consortium. The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: a report from the pediatric sedation research consortium. *Anesth Analg* 2009; **108**:795–804.

## EXECUTIVE SUMMARY

Question	Consensus	Level of evidence	Grade of recommendation
1. What types of co-morbidities and patients require evaluation and management of procedural sedation and analgesia by an anaesthesiologist?			
1a. Patients with severe cardiovascular diseases	Very good	A	Strong
1b. Patients with documented or suspected risk of obstructive sleep apnoea syndrome	Very Good	B	Strong
1c. Patients with morbid obesity (BMI greater than 40 kgm <sup>-2</sup> )	Very good	A	Strong
1d. Patients with chronic renal failure (glomerular filtration rate below 60 ml min <sup>-1</sup> 1.73 m <sup>-2</sup> for more than 3 months or stage 3A)	Very Good	B	Weak
1e. Patients with chronic hepatic disease (model for end-stage liver disease score 10)	Very good	A	Strong
1f. Elderly patients (older than 70 years)	Very good	A	Strong
1g. Patients with American Society of Anesthesiologists' physical status III to IV	Very good	B	Strong
2. What are the requirements to provide well tolerated procedural sedation and analgesia?			
2a. Adequate upper airways evaluation	Very good	B	Strong
2b. Adequate location/monitoring and anaesthesia environment	N/A	N/A	Strong
2c. All personnel in charge of the procedural sedation and analgesia should be certified for cardiopulmonary resuscitation	Very good	B	Strong
2d. Minimal skills for training for non-anaesthesia providers dedicated to procedural sedation and analgesia	Very Good	B	Strong
2e. Acquisition/maintenance of minimum technical skills for non-anaesthesia personnel: procedural sedation and analgesia should be carried out only in locations where an anaesthesiologist is immediately available	Very good	C	Strong
2f. Patient information on procedural sedation and analgesia and the personnel dedicated to provide procedural sedation and analgesia	very good	B	Strong
2g. Immediate access to equipment for resuscitation	Good	B	Strong
2h. Location and environment for procedural sedation and analgesia	Good	C	Strong
2i. Pre-sedation fasting	Good	C	Weak
2j. Detailed knowledge of the pharmacology of drugs used for procedural sedation and analgesia			
2k. Detailed knowledge of the monitoring devices and interpretation of the information provided by the monitors			
2k. i. Clinical observation: Continuous visual bedside observation of the patient represents the basic level of clinical monitoring during and after any procedural sedation	Very good	B	Strong
2k. ii and iii. Non-invasive blood pressure and ECG: intermittent non-invasive measurements of blood pressure and continuous ECG monitoring are considered mandatory in all patients undergoing procedural sedation	Very good	B	Strong
2k. iv. Pulse oximetry: the most important device for clinical bedside monitoring should be used in all patients undergoing procedural sedation	Very good	B	Strong
2k. v. Capnography: by facilitating early detection of ventilation problems should be used in all patients undergoing procedural sedation	Very good	A	Strong
2k. vi. Processed electroencephalogram monitors might be considered for monitoring of procedural sedation particularly when using propofol	Good	B	Weak
2l. Knowledge of the major type of complications and their management	Very good	B	Strong
2m. Knowledge of the interventions that may be used if required			
2m. i. Use of supplemental oxygen	Good	B	Strong
2m. ii. Haemodynamic support (outside cardiopulmonary resuscitation)	Moderate	N/A	Weak
3. How should recovery after procedural sedation and analgesia be managed?			
Patients must be monitored in a recovery room for at least 30 min after procedural sedation and analgesia	Good	B	Strong
4. Who should evaluate non-anaesthesia personnel and according to what criteria to establish they are adequately trained to perform procedural sedation and analgesia?			
Anaesthesiologists (both anaesthesiologists and anaesthesia nurses in some countries) are the main specialists involved in PSA, and they are able to manage patients at various levels of sedation and general anaesthesia while mastering upper airways, ventilation and circulation.	Good	N/A	Strong